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ABSTRACT 
 Macroautophagy (autophagy) is intimately linked with cell death and often allows 
cancer cells to evade apoptosis. This has prompted clinical trials to combine autophagy 
inhibitors with other drugs with the aim of reducing patient tumor burden by increasing 
the likelihood of cancer cells dying. However, the molecular basis for such effects is 
unknown. I describe a transcriptional mechanism that connects autophagy to apoptosis. 
The autophagy-regulating transcription factor, FOXO3a, is itself turned over by basal 
autophagy creating a potential homeostatic feedback loop. Increased FOXO3a upon 
autophagy inhibition stimulates transcription of the pro-apoptotic PUMA gene to cause 
apoptosis sensitization. This mechanism explains how autophagy inhibition can 
sensitize tumor cells to chemotherapy drugs and allows an autophagy inhibitor to 
change the action of an MDM2-targeted drug from growth inhibition to apoptosis, 
reducing tumor burden in vivo. Thus, a link between two processes—autophagy and 
apoptosis—mediated via a single transcription factor binding site in the genome can be 
leveraged to improve anti-cancer therapies. Also, I provide insight into FOXO3a 
regulation by autophagy, which is mechanistically distinct from its canonical regulation 
by the proteasome. Lastly, I developed an optogenetic tool to inhibit autophagy in a 
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rapid, transient, and spatial manner, allowing us to uncover other mechanisms that link 
autophagy to cell death.  
 
The form and content of this abstract are approved. I recommend its publication. 
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Overview of autophagy and cell death 
Macroautophagy (hereafter autophagy) is an evolutionarily-ancient mechanism 
by which cellular material is delivered to lysosomes for degradation. Autophagy is best 
understood in the context of nutrient deprivation, and is often viewed as a way to 
maintain cellular homeostasis by recycling old or damaged organelles. Christian de 
Duve, a Belgian biochemist, first coined the term ‘autophagy’ during a lysosome 
conference in 1963, and since then the molecular mechanisms of autophagy have 
continued to emerge. The Nobel Prize for Physiology or Medicine was awarded to the 
Japanese cell biologist Yoshinori Ohsumi in 2016 for his ground-breaking studies 
elucidating the genetic components of autophagy in Saccharomyces cerevisiae 
(Mizushima et al., 1998; Takeshige et al., 1992; Tsukada and Ohsumi, 1993). 
Autophagy is conserved from yeast to humans, and is intimately intertwined with other 
cellular processes, including programmed cell death. Autophagy and cell death have 
some shared molecular machinery and recent work suggests that autophagy has great 
influence over a cell’s decision to live or die. Numerous studies demonstrate that 
autophagy plays a role in many physiological processes, and there are dozens of 
ongoing clinical trials aiming to pharmacologically manipulate autophagy in humans with 
                                                 
 
1. Portions of this chapter were published with permission from FEBS Journal: 
Recent insights into cell death and autophagy.  




the goal of mitigating disease. Understanding the cellular mechanisms by which 
autophagy regulates cell fate is critical for knowing how autophagy alteration might be 
beneficial in diseases where too much or too little cell death takes place e.g. 
neurodegenerative diseases and cancer, respectively. 
As we consider how autophagy affects cell death, it is important to note that 
autophagy can determine whether or not cells die without directly affecting the cell 
death machinery. For example, it is well established that autophagy is critical for 
preventing cell death due to amino acid starvation, but this doesn’t necessarily mean 
that the apoptosis and necrosis mechanisms that cause amino acid starved cells to die 
are controlled by autophagy. Instead, autophagy can be protective here simply because  
autophagy degrades proteins, thereby providing the cell with the amino acids it needs to 
avoid activating those cell death mechanisms in the first place. Similarly, in mice genetic 
inactivation of autophagy in neurons leads to accumulation of aggregated proteins and 
eventual neuronal cell loss (Hara et al., 2006; Komatsu et al., 2006); however, this 
doesn’t mean that autophagy was directly controlling the activity of the cell death 
machinery in those neurons. Instead, in this case, it is thought that autophagy is 
removing the toxic protein aggregates so that a death signal was never activated. In 
general, I will ignore this type of indirect mechanism whereby autophagy removes a 
toxic signal to focus on recent findings that relate to more direct autophagy control of 
distinct programmed cell death pathways. My work in this thesis will reveal some of 
these direct mechanisms.  
 Autophagy’s influence over cell death decision making is complicated by the fact 
that autophagy’s role in determining whether a cell should live or die goes both ways—
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autophagy inhibition can result in more or less cell death. Autophagy may also 
differentially affect different types of cell death. In this thesis, I will discuss literature and 
present work that helps make sense of this seemingly inconsistent role of autophagy in 
influencing a cell to live or die. 
The direct mechanisms by which autophagy positively regulates cell death are 
still being uncovered. We arguably have better evidence for autophagy promoting cell 
death under physiological conditions than we do for autophagy providing a general 
protective effect. As I will discuss below, there are numerous examples in development 
and under normal physiological conditions where autophagy is required for cell death 
(Nelson and Baehrecke, 2014). This cell death depends on autophagy because deletion 
of core components of the autophagy machinery results in less death.  
There are some direct molecular mechanisms explaining how autophagy 
prevents cell death. For example, in Chapter III, I describe a direct mechanism that 
explains how autophagy can protect cells from apoptosis by selectively degrading a 
transcription factor needed to promote cell death. Preventing the degradation of this 
transcription factor by blocking autophagy promotes apoptosis sensitization; this 
provides a specific mechanism whereby the autophagic degradation of a pro-apoptotic 
protein allows cells to evade apoptosis. I will discuss the practical implications of this 
mechanism in targeting autophagy in cancer cells.  
It is now becoming clear that autophagy does in fact directly regulate the cell 
death machinery both positively and negatively depending on the death stimulus, cell 
type, and context. Autophagy can also influence different types of cell death (Figure 1.1) 
(Tait et al., 2014).  
Figure 1.1
Cell death modes. Adopted from Hotchkiss et al 2009 NEJM
4
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I aim to emphasize three important points: (1) Programmed cell death 
mechanisms and autophagy are indeed intimately linked. (2) The basis for autophagy 
influencing cell-fate decisions—whether to live or die—depends on which proteins are 
recruited to autophagosomes for lysosomal degradation. (3) Where and when the 
autophagy pathway—early versus late stages, before or after a death stimulus—is 
manipulated by genetic changes or pharmacological agents should be considered when 
trying to influence survival or cell death.  
Autophagy regulation 
Autophagy degrades cytoplasmic substrates to obtain energy and metabolic 
building blocks, especially when the cell is subjected to nutrient deprivation (Mizushima, 
2007). Autophagy is also necessary for the homeostasis of organelle integrity, 
clearance of aggregated proteins, tissue remodeling during development, and 
resistance to infectious agents like bacteria and viruses. The signaling associated with 
autophagy is best understood in the context of coping with nutritional stress and 
maintaining cellular fitness. Many studies have concentrated on amino acid and insulin-
dependent signaling involving mTOR signaling. Upstream of mTOR, the 5’ AMP-
activated protein kinase (AMPK) phosphorylates TSC2 in response to a low ATP/AMP 
ratio, leading to mTOR inactivation and autophagy induction. Other important 
complexes include the ULK1 initiation complex and the Beclin1-VPS34 PI3 Kinase 
complex, which are important for nucleation of the membrane that will eventually form 
the autophagosome (Figure 1.2) (Mizushima, 2007). In response to such signaling, 
coordinated actions of more than 30 ATG (autophagy-related genes) proteins promote 
the nucleation and elongation of an isolation membrane for engulfing cytosolic  
Figure 1.2
The autophagy pathway. Adopted from Mulcahy-Levy et al 2017 Nat. Rev. Cancer
6
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substrates into an autophagosome. Two ubiquitin-like conjugation systems cause 
elongation of the membrane and formation of the autophagosome. One of these 
systems is the covalent conjugation of ATG12 to ATG5, which interacts with ATG16L to 
form the ATG5-ATG12-ATG16L complex. The second system conjugates a lipid, 
phosphatidylethanolamine, to LC3 (and the other family members, LC3A, B, C, 
GABARAPL1, and GABARAPL2) resulting in the autophagosome-associated LC3-II 
protein, which is commonly monitored as a measure of autophagic activity in cells. At 
this stage, cellular material including proteins and organelles are either specifically 
recruited to the autophagosomal structures or, in the case of bulk non-specific 
autophagy, randomly captured. After fusion of the membranes to make an intact vesicle 
containing the cargos that will eventually be degraded, the resulting double-membrane 
vesicle fuses with a lysosome to form an autolysosome. Then, lysosomal enzymes 
hydrolyze the proteins, lipids and nucleic acids contained in the autophagosomes. The 
completion of this process is termed autophagic flux, and the magnitude of this flux can 
be measured on western blots by the amount of lipidated autophagosome-associated 
protein LC3-II that accumulates with or without blockade of the lysosomal fusion step. 
Alternatively, fluorescent labeling of LC3 can allow for tracking the redistribution of LC3 
to autophagosomes. By using fluorescent tags with different pH sensitivities, it is 
possible to measure both the formation of autophagosomes and their fusion with 
lysosomes. Autophagy substrates are often recruited to autophagosomes by 
ubiquitylation, and recognized by adaptor proteins such as SQSTM1 (p62), which 
contain an LC3-interacting region (LIR). These adaptor proteins are degraded along 
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with the cargo, and their turnover can therefore also be used to measure autophagic 
flux.  
When I discuss “early” steps in the autophagy process, I am referring to the 
activities of ATG proteins and signaling complexes necessary for autophagosomal 
nucleation, elongation, and maturation but not fusion with the lysosome and degradation 
of the cargo. For example, inhibition of early autophagy could be achieved by 
pharmacologically inhibiting the phosphatidylinositol 3-kinase (VPS34) with a kinase 
inhibitor, or the genetic knock down of ATG7 thus preventing the protein conjugations 
necessary for autophagosomal membrane elongation. Conversely, when I refer to “late” 
steps in autophagy, I mean the degradation of the autophagosome and its cargo by the 
lysosome. As I will discuss, interference with autophagy at these different steps may 
sometimes have quite different effects on the cell fate decision.  
Apoptosis regulation 
Caspase-dependent apoptosis is by far the best understood mode of 
programmed cell death. We usually think of apoptosis as being driven by either intrinsic 
or extrinsic pathways (Figure 1.3). Extrinsic apoptosis occurs through ligand binding to  
cell surface receptors such as CD95, also known as Fas, and tumor necrosis factor-
related apoptosis inducing ligand (TRAIL). Activation of these death receptors causes 
formation of various protein complexes that ultimately serve to aggregate an initiator 
caspase (caspase-8). In some cells, this occurs efficiently enough to activate sufficient 
effector caspase (e.g. caspase-3) activity to kill the cell. However, in most cells, the 
active caspase-8 causes cleavage of the BH3-only protein BID to activate the so-called 
“intrinsic” apoptosis pathway and this is needed to induce enough caspase activity to  
Figure 1.3




cause apoptosis. The intrinsic pathway is also activated by apoptosis stimuli that do not 
work through death receptors.  
Intrinsic apoptosis (Figure 1.3) is characterized by the summation of pro- and 
anti-death signals converging at mitochondrial membranes that become permeabilized 
(MOMP—mitochondrial outer membrane permeabilization), leading to the release of 
mitochondrial intermembrane proteins. The key proteins include cytochrome c and 
Smac/Diablo, an inhibitor of caspase inhibitors that normally keeps caspases in check. 
The release of cytochrome c interacts with Apaf1 to form a scaffold called the 
apoptosome, leading to the activation of the initiator caspase-9. MOMP is followed by 
rapid cell death because the combination of caspase activation on the apopotosome 
along with simultaneous block of caspase inhibitors starts a cascade of active caspases 
that cleave hundreds of cellular substrates to cause cellular demise.  
Bcl-2 family proteins control MOMP through protein-protein interactions. The anti-
apoptotic BCL-2 proteins Bcl-2, Bcl-xL, and Mcl-1 prevent activation of the pro-apoptotic 
proteins Bax and Bak, which form the pores in the mitochondrial membrane that defines 
MOMP. However, upon the accumulation of cellular stress, there is a synchronized 
effort by BH3-only members, like BID, BIM, BAD, PUMA, and NOXA, that inhibit the Bcl-
2 proteins, or directly activate Bax and Bak to promote MOMP. A ~26 residue 
amphipathic helix comprises the BH3 domain that binds with high affinity to a 
hydrophobic groove of BCL-2 proteins to inhibit their anti-apoptotic activity. 
MOMP is commonly thought of as a ‘point of no return’ that defines the cell’s 
commitment to apoptosis. However, new evidence questions this dogma by 
demonstrating that a small population of mitochondria in the cell may actually undergo 
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MOMP, yet not result in the death of the cell. This has been termed “Incomplete” (Tait et 
al., 2010) or “Minority” MOMP (Ichim et al., 2015). These effects whereby a cell 
activates incomplete MOMP and then recovers can have profound biological effects. 
Indeed, it was recently demonstrated that minority MOMP and caspase activation is 
sufficient to promote pro-tumorigenic effects in cells (Ichim et al., 2015; Liu et al., 2015).  
Moreover, bursts of caspase activity that are not sufficient to cause the cell to die occur 
during development (Tang et al., 2015), suggesting that these effects may be important 
in normal biological processes. Thus, complete MOMP causes enough caspase 
activation to cleave sufficient caspase substrates that the cell is destined to die with the 
morphology associated with canonical apoptosis, like plasma membrane blebbing and 
nuclear condensation etc. However, incomplete MOMP allows cells to recover after 
activating an insufficient level of caspases to cause death. 
Understanding canonical apoptosis execution and what determines apoptosis 
threshold is still an active area of research in cancer therapy. Cytotoxic chemotherapies 
(e.g. microtubule-targeted agents and DNA damaging agents) have cured millions of 
patients with otherwise fatal disease. That is, a patient presents in the clinic with a fatal 
cancer, and goes into complete remission following a defined anti-cancer regimen 
(Letai, 2015). Conventional chemotherapies take advantage of the differences in 
mitochondrial priming to apoptosis between ‘normal’ tissue and cancer cells; numerous 
studies have demonstrated that differential priming to apoptosis can predict clinical 
responses to cytotoxic chemotherapies (Ni Chonghaile et al., 2011). Understanding the 
mechanisms that regulate the distance that cancer cells are from the proverbial ‘cliff’—
their likelihood of undergoing apoptosis—will be critical for the evolution of cytotoxic 
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chemotherapies. My work in this thesis will argue that autophagy levels in cancer cells 
dictate their apoptotic threshold. 
 One way in which autophagy controls cell death is by regulating apoptotic 
proteins, like PUMA. PUMA, or p53-upregulated modulator of apoptosis, is a pro-
apoptotic BH3-only protein that has the ability to bind to all Bcl-2 proteins, localizes to 
mitochondria, and promotes cytochrome c release (Nakano and Vousden, 2001; Yu and 
Zhang, 2008). PUMA contains three coding exons (exons 2-4) and two non-coding 
exons (1a and 1b), all of which (except 1b) are conserved in mice (Yu and Zhang, 
2008). The PUMA protein has two functional domains; the BH3 domain and the 
mitochondrial localization signal. PUMA indirectly affects MOMP by directly blocking 
anti-apoptotic Bcl-2 proteins, which sustain inhibition on Bax and Bak (Yu and Zhang, 
2008). PUMA expression is normally kept low, but can be increased by transcription 
factors FOXO3, E2F1, p53, and p73 following a range of stress stimuli (Hershko and 
Ginsberg, 2004; Melino et al., 2004; Nakano and Vousden, 2001; You et al., 2006; Yu et 
al., 2001). PUMA has also been shown to be regulated by phosphorylation at serine 10, 
which leads to increased proteasomal turnover (Fricker et al., 2010). These data show 
that PUMA can be regulated in response to a range of cellular stresses.  
Forkhead Box transcription factors in cell death and autophagy 
Forkhead Box (FOX) transcription factors are increasingly recognized as players 
in many different signaling pathways, including DNA damage, metabolism, apoptosis, 
cell cycle, oxidative stress, and cell differentiation (Figure 1.4) (Huang and Tindall, 
2007). In addition, their activity has been shown to influence programmed cell death, 
autophagy, and ageing. There are numerous studies providing evidence that the  
Figure 1.4
The biological roles of FOXO transcription factors. Adopted from Calnan and Brunet 
et al 2008 Oncogene
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ortholog of FOXO, daf-16, is necessary to mediate the life-extension properties of 
insulin growth factor receptor mutations (daf-2) in Caenorhabditis elegans (Henderson 
and Johnson, 2001; Lin et al., 1997; Ogg et al., 1997). In humans, there are 
associations between genetic variation in FOXO3a and longevity (Donlon et al., 2012; 
Willcox et al., 2008). The first Forkhead protein was identified as a homeotic Drosophila 
melanogaster gene, and since then over 100 forkhead genes, with 19 human subgroups 
ranging from FOXA to FOXS, have been identified (Weigel et al., 1989). Here, I discuss 
the significance of the FOXO subclass of the forkhead box transcription factors, which 
are conserved from Caenorhabditis elegans to humans, are expressed in all human 
tissues, and consist of FOXO1, FOXO3, FOXO4, and FOXO6. The DNA binding 
domain of these proteins, known as the Forkhead domain appears as “butterfly-like” in 
X-ray crystallography studies, which is created by three α-helices and three 𝛽-sheets 
with two wing-like loops (Maiese, 2015). Their protein structure is described as a 
“winged helix” with 14 protein-DNA contact points, with the primary recognition region at 
α-helix H3 (Clark et al., 1993). FOXO transcription factors often act as transcriptional 
activators and bind to DNA at the core consensus sequence of TTGTTTAC (Furuyama 
et al., 2000; Xuan and Zhang, 2005). There are many post-translational modifications 
(PTMs) that can occur in the Forkhead domain that regulate this DNA binding ability. 
FOXO transcription factor activity is primarily regulated through post-translational 
modifications, including phosphorylation, mono-ubiquitination, poly-ubiquitination, and 
acetylation (Brunet et al., 1999; Brunet et al., 2001; Li et al., 2016; van der Horst et al., 
2004; Yuan et al., 2008) (Figure 1.5). The effect of these modifications can also 
influence FOXO localization, binding partners, and DNA affinity  
Figure 1.5
Post-translational modifications of FOXO transcription factors. Adopted from 
Calnan and Brunet 2008 Oncogene
15
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(Calnan and Brunet, 2008). Phosphorylation events often regulate the 
nuclear/cytoplasmic shuttling acting as effectors in many signaling pathways intended to 
alter transcription. The PI3K-Akt pathway and the serum and glucocoticoid-induced 
kinase (SGK) are known to phosphorylate FOXOs on conserved residues (T32 and 
S253 in FOXO3) to promote cytoplasmic sequestration via binding to the chaperone 
protein 14-3-3 (Brunet et al., 1999; Li et al., 2007; Obsilova et al., 2005). Further 
regulation of FOXO transcription factors includes protein stability regulation by the 
proteasome pathway in response to insulin and growth factors (Aoki et al., 2004; Huang 
et al., 2005; Matsuzaki et al., 2003; Plas and Thompson, 2003). Taken together, the 
PI3K-Akt signaling node leads to both the cytoplasmic sequestration and proteasome-
mediated degradation of FOXO transcription factors in response to insulin signaling. 
The RAS-ERK signaling pathway has also been shown to regulate FOXO3a by 
phosphorylation at Ser 294, Ser 344, and Ser 425, leading to increased Mouse double 
minute 2 homolog (MDM2)-dependent proteasomal degradation (Yang et al., 2008).  
There is mounting literature that FOXO transcription factors play a role in 
autophagy regulation. The most compelling of these studies involves FOXO3a 
orchestrating a protective gene program in hematopoietic stem cells (HSC) by 
upregulating core autophagy genes and autophagy regulators in response to cytokine 
withdraw (Warr et al., 2013a). The autophagy induction mediated by FOXO3a activation 
poised HSCs for adaptation to this by this insult, protected from metabolic crisis, and 
allowed for HSC survival (Warr et al., 2013a). Another study found that FOXO1 was 
important for autophagy induction by eliciting its actions in the cytoplasm, independent 
of its transcriptional activity. In response to starvation or oxidative stress, FOXO1 was 
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determined to be acetylated and bound to the autophagy-related E1 conjugation 
enzyme ATG7, allowing for autophagy induction and eventually cancer cell death (Zhao 
et al., 2010).  
 The transcriptional and epigenetic mechanisms that regulate autophagy are 
becoming increasingly appreciated. A recent study implicated FOXO3a in a novel 
signaling axis involving AMPK-SKP2-CARM1 (AMP-activated protein kinase--S-phase 
kinase associated protein 2--Coactivator-associated arginine methyltransferase 1) in 
regulating autophagy following starvation. This seemingly complex mechanism 
suggested that following starvation, AMPK phosphorylates FOXO3a in the nucleus, 
leading to the transcriptional repression of SKP2. This repression then leads to CARM1 
stabilization, and increased histone H3 Arg17 dimethylation. CARM1 mediates co-
activator functions through the transcription factor EB (TFEB), leading to autophagy and 
lysosomal-related gene activation (Shin et al., 2016). These studies point to the need for 
integrating both transcriptional and epigenetic datasets to understand the outcome of 
transactivation of transcription factors like FOXOs. Of the thousands of FOXO 
transcriptional targets, which are important for mediating the primary effects on cell 
death or cellular stresses? Are there modifications or other unknown regulatory 
mechanisms that orient FOXO activity toward certain targets upon autophagy 
manipulation? Which kinds of FOXO transcriptional targets are regulated early and late 
in response to stress or other stimuli? With the advent of a novel optogenetic system to 
inhibit autophagy that I describe in Chapter VI, I will be able to tackle some of these 
questions.  
A recent study (Li et al., 2016) determined that FOXO3a is oriented toward 
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specific targets by a phosphorylation event at S574 by c-Jun N-terminal Kinase (JNK)—
phosphorylated FOXO3a bound at pro-apoptotic promoters as measured by ChIP in 
response to ethanol or lipopolysaccharide. This study demonstrates that a post-
translational modification can determine the specificity of a transcriptional program 
toward a specific cell fate decision. Future studies should examine these questions to 
determine their role in diseases and biological processes where FOXO transcription 
factors are believed to be involved.  
How autophagy regulates apoptosis 
The Thorburn laboratory recently described a mechanism by which autophagy 
controls apoptosis; autophagy regulates the PUMA protein to govern the timing and 
extent of MOMP, and subsequently regulates the timing and efficiency of apoptosis 
(Thorburn et al., 2014). This study found that as compared to autophagy competent 
cells, autophagy deficient cells are highly sensitized to Tumor Necrosis Factor-Related 
Apoptosis Inducing Ligand (TRAIL)-induced apoptosis. Importantly, the majority of 
autophagy’s ability to inhibit apoptosis in this context was due to this mechanism 
because PUMA knockdown was sufficient to avoid sensitization to apoptosis when 
autophagy is inhibited. This indicates that autophagy is providing protection from TRAIL 
through the ability of autophagy to regulate constitutive levels of PUMA. This example 
defines a mechanism by which autophagy can protect cells from a canonical apoptotic 
stimulus by controlling the level of a key regulator that makes the rate limiting step in 
apoptosis– i.e. MOMP– work more efficiently. In Chapter III, I take these studies a step 
further by uncovering a transcriptional mechanism that explains how autophagy 
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regulates PUMA levels, and show in Chapter IV that this mechanism can be leveraged 
to improve anti-cancer drugs (Fitzwalter et al., 2018).   
The Thorburn laboratory also recently reported (Gump et al., 2014) that in a 
population of cells, there are transient cell-to-cell variations in basal autophagy flux that 
dictates cell fate in both a cell-type-specific and stimulus-specific fashion. For example, 
distinct populations of cells with high or low autophagy flux respond very differently to 
death receptor activation. Fas ligand and TRAIL act in similar and well-understood 
ways, utilizing many of the same pathway components to elicit apoptosis. So, it was 
surprising when cell sorting to isolate cells that were undergoing high or low levels of 
autophagy, and treating these with Fas or TRAIL produced completely opposite results. 
High autophagy cells were sensitized to Fas ligand-induced apoptosis, but resistant to 
TRAIL treatment. As explained above, the protective effect of autophagy on TRAIL-
induced apoptosis can be largely explained by PUMA being lower when autophagy is 
high, thus making MOMP more efficient. What explains the opposite effect when the 
apoptotic stimulus is the very similar death agonist Fas Ligand? 
The answer was that the differential responses to two canonical death ligands is 
a result of what the high autophagy cells are or are not degrading. The key was the 
selective degradation of a phosphatase, FAP-1, which is a negative regulator of FAS 
signaling, but does not affect TRAIL signaling. This degradation of a negative regulator 
of FAS signaling was sufficient and necessary to explain how high autophagy can 
promote Fas-induced apoptosis. And, since FAP-1 has no effect on TRAIL receptors, 
this also explains why only autophagy’s protective effects were seen with TRAIL-treated 
cells in this case. This example demonstrates how autophagy can both positively and 
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negatively influence cell fate. The degradation of a negative apoptosis regulator results 
in more death in high autophagy cells, while autophagy regulation of a positive regulator 
of apoptosis leads to less death in high autophagy cells. This mechanism of apoptosis 
promotion by autophagy is conceptually similar to another study performed in 
Drosophila nurse cells during oogenesis; apoptosis is promoted by autophagic 
degradation of a negative regulator (dBruce) that controls the apoptosis machinery 
(Nezis et al., 2010). The difference here is that the FAP-1 mechanism affects only 
apoptosis induced by Fas Ligand, whereas the dBruce degradation in the nurse cells 
removes an inhibitor of a caspase inhibitor, sensitizing them to any stimulus that 
activates caspases.  
I just discussed how autophagy influences cell death by selective degradation of 
pro- or anti-apoptotic proteins. An intriguing story where autophagosomal membranes 
serve as platforms for death signaling complexes offers another mechanistically distinct 
example of how the autophagy machinery can influence cell fate. Experiments with the 
sphingosine kinase inhibitor (SKI-I), which promotes cell death through the suppression 
of sphingosine 1-phosphate, showed caspase-dependent cell death occurred only in the 
presence of functional autophagy (Young et al., 2012). Further, SKI-I was demonstrated 
to promote the translocation of caspase-8 homocomplex and Fas-associated protein 
with death domain (FADD) to ATG5-positive autophagosomal membranes, forming a 
scaffold for the efficient formation of an intracellular death-inducing signaling complex 
(iDISC). This death was abrogated by ATG5 depletion, which resulted in lower 
activation of mitochondrial amplification loop that is initiated by caspase-8. A follow-up 
study proposes that ATG2A/B deletion causes an accumulation of immature 
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autophagosomal membranes, and promotes the recruitment of the iDISC signaling 
complex (Tang et al., 2017). The authors argue that targeting autophagosomal closure 
may be a novel target to switch cytoprotective autophagy to apoptosis. Overall, these 
studies show a mechanism of apoptosis that is dependent on autophagosomal 
structures but not necessarily the whole process of autophagy whereby the material 
sequestered in the autophagosome is degraded. 
Two important implications of this mechanism whereby the autophagy machinery 
alters signaling by serving as a scaffold should be considered. First, there may be 
different effects on the outcome of the cell depending on whether basal autophagy or 
stimulus-induced autophagy is manipulated. For the anti- and pro-apoptotic effects that 
are ultimately due to altering levels of apoptosis regulators such as PUMA, dBruce or 
FAP-1, autophagy’s effects must be mediated prior to the initiation of the death signal if 
they are to alter the likelihood that the subsequent apoptosis stimulus will be sufficient 
to cause the cells to die. Indeed, when cells were separated into high and low 
autophagy from a population, the study found that this predicted their likelihood to 
undergo apoptosis that wasn’t even initiated until several hours after the separation of 
the cells into the two groups (Gump et al., 2014). This is a case whereby the effects of 
basal autophagy that occur before the apoptosis signal are critical for deciding whether 
or not cells will die at a later time. Not surprisingly then, manipulations that affect such 
basal autophagy can influence these mechanisms (Yonekawa et al., 2015). When 
autophagic structures are working by forming a scaffold for efficient formation of death 
inducing protein complexes as in the case with the intracellular DISC formed after SKI-I 
inhibitor treatment, autophagy is having its effects after initiation of the death stimulus. 
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These kinds of effects are, therefore, more likely to be influenced not by the basal 
autophagy that occurred before the death stimulus, but instead by the induced 
autophagy that occurs in response to the stimulus. Since many apoptotic stimuli (e.g. 
drugs that kill cells as well as pure apoptosis inducers like the death receptor agonists) 
also induce autophagy, it has been assumed that this induced autophagy is doing the 
same things to the cell death machinery as the ongoing basal autophagy does. That’s 
not necessarily true. To date, it has been impossible to test such ideas because we 
usually design experiments to determine how autophagy affects cell death by inhibiting 
autophagy using genetic approaches (knockout or knockdown of essential ATGs, 
expression of dominant negatives etc.) that take several days to become effective 
(Staskiewicz et al., 2013). Technical advances will be needed to address these 
questions because one needs a way to very rapidly, selectively and reversibly target 
stimulus-induced autophagy without affecting basal autophagy in order to test if both 
types of autophagy have the same effects, or not. To tackle this problem, I describe in 
Chapter VI the development of an optogenetic system to inhibit autophagy with light.  
Second, interference with autophagy at different steps in the process may 
sometimes have the same effects or different effects on a cell’s likelihood of dying. If the 
important mechanism is regulation of proteins like FAP-1 or PUMA, it most likely doesn’t 
matter how autophagy is blocked—if you block formation upstream of autophagosomal 
structures or degradation of cargo, similar effects are expected. Indeed, that’s what we 
saw with FAP-1– genetic inhibition of autophagosome formation gave similar effects to 
blocking lysosomal function. However, if autophagy’s role in regulating apoptosis is by 
providing scaffolding structures as discussed above, one might expect that inhibiting 
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formation of autophagosomal structures would block cell death, while inhibiting their 
degradation (e.g. by blocking the lysosome) might promote these effects by causing 
more scaffolding. 
There are hints in the literature (Tang et al., 2017) where apoptosis inducing anti-
cancer drugs are affected oppositely depending on whether autophagosome formation 
versus degradation are targeted. Do these kinds of mechanistic differences explain 
such effects? The answer to this question is important because although we are already 
treating cancer patients with lysosomal inhibitors, other autophagy inhibitors that affect 
early steps in the process are being developed (Bago et al., 2014; Dowdle et al., 2014; 
Egan et al., 2015; Ronan et al., 2014). For example, the VPS34 kinase inhibitor, 
SAR405, is a potent (KD=1.5 nM) and selective compound targeting the ATP binding 
cleft. SAR405 was shown to inhibit starvation-induced autophagy by limiting the 
formation of lipidated LC3, reducing GFP-LC3 puncta, and causing the accumulation of 
a receptor protein p62 (Ronan et al., 2014). Compounds like SAR405 that target the 
initiation of autophagy may prove to be efficacious in clinical trials as independent 
therapies, or useful alongside late-stage inhibitors like chloroquine. One could also 
imagine a situation in which these drugs might have the opposite effect that is hoped for 
(i.e. inhibit rather than promote tumor cell death) e.g. by interfering with scaffolding 
activities and this might be highly context dependent. Namely, if a cell death complex 
requires an autophagosomal scaffold then blocking autophagosome formation may 
mitigate death, whereas blocking autophagosome-lysosome fusion could potentiate 
death. As autophagy inhibitors increasingly become a part of clinical development, 
understanding the consequences of blocking each step in the autophagy pathway will 
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be important. Below, I will discuss how another type of cell death, programmed 
necrosis, may be reliant on autophagosomes as signaling scaffolds.  
How apoptosis regulates autophagy 
Apoptosis can directly influence autophagy. For example, Beclin 1 is a substrate 
for cleavage by caspase-3. Two caspase cleavage sites in Beclin 1 were discovered 
(Zhu et al., 2010), resulting in reduced affinity for Bcl-2, a reduction in autophagy, and 
an enhancement of apoptosis in HeLa cells. The cleavage of Beclin 1 may be a way to 
help the cell fully commit to apoptosis by putting the brake on autophagy induction, 
reducing the likelihood of cellular recovery. Other essential autophagy proteins are also 
targeted by caspases. The autophagosomal biogenesis regulatory protein ATG3 is a 
substrate for caspase-8 cleavage following the activation of extrinsic apoptosis (Oral et 
al., 2012). This cleavage site in ATG3 is conserved in humans, mice, rats, zebra fish, 
frogs, worms, and baker’s yeast suggesting a conserved regulatory role. Cleavage of 
ATG3 following a death receptor signal inactivated autophagy, but the expression of a 
non-cleavable ATG3 could re-establish autophagic activity. Further, the autophagy 
protein AMBRA1 (activating molecule in BECN1-regulated autophagy) is degraded by 
calpains and caspases, and expressing a cleavage-resistant mutant leads to apoptosis 
avoidance by prolonging autophagy induction (Gu et al., 2014).  
BCL family proteins regulate autophagy initiation, as well as control the balance 
of pro- and anti-apoptotic signals. One of the best examples of this regulation is the 
ability of BH3 (BCL-2 homology 3)-only proteins to neutralize BCL-2 anti-apoptotic 
proteins, stimulate pro-apoptotic proteins, and displace protein interactions that put the 
brake on autophagy induction. The subcellular localization and phosphorylation status 
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of these BH3-only proteins dictate the direction toward survival or undergoing apoptosis, 
and the tendency to promote autophagy. BH3-only proteins, like PUMA, NOXA, NIX, 
BID, and BNIP3, disrupt inhibitory interactions between the BCL-2 proteins (Bcl-2, Bcl-
XL, Mcl-1) and the autophagy regulator Beclin 1 (BECN1) (Pattingre et al., 2005). 
Relieving the inhibition of BECN1 by Bcl-2 or Bcl-XL displacement allows for the 
activation of a PI3 Kinase called vacuolar protein sorting 34 (VPS34), resulting in the 
nucleation of an isolation membrane. This regulation of Bcl-2 protein and subsequent 
displacement from BECN1 is also controlled by phosphorylation, e.g. by the stress-
activated c-Jun N-terminal protein kinase 1 (JNK1) (Wei et al., 2008). Although 
understanding how apoptosis influences autophagy is important, the work presented in 
this Thesis mainly focuses on how autophagy regulates apoptosis. 
Autophagic cell death—autophagy as a direct cause of cell death  
 The mechanisms described above involve autophagy interplay with apoptosis; 
however, autophagy may also regulate non-apoptotic cell death mechanisms where 
there is no need for caspase activation in order for the cell to die. For example, it was 
shown that acute expression of oncogenic H-RAS can cause caspase-independent 
death with characteristics of autophagy (Elgendy et al., 2011). This autophagic cell 
death was mediated by and dependent on Ras-induced expression of the pro-apoptotic 
protein, Noxa, and Beclin 1. These findings provided the first unequivocal genetic 
evidence for autophagy-dependent death in mammalian cells in response to a specific 
signaling event and although seen in an artificially controlled system, suggest that 
autophagic cell death may, under some circumstances, provide a mechanism to limit 
the oncogenic potential of dysregulated RAS signaling.  
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A requirement for functional autophagy for programmed cell death has been 
most clearly shown in vivo in developmental systems that are genetically tractable, such 
as Drosophila (Nelson and Baehrecke, 2014). For example, the first clear genetic 
evidence that autophagy is required for “physiological” cell death in vivo came from the 
demonstration that autophagy is induced just before salivary gland cell death, and 
salivary glands are not properly degraded in ATG mutants (Berry and Baehrecke, 
2007). During salivary gland degradation, autophagic cell death is thought to take place 
alongside caspase-dependent apoptosis. Conversely, as mentioned above, during 
Drosophila oogenesis, autophagy controls cell death by promoting caspase activation 
and subsequent apoptosis (Nezis et al., 2010). In other contexts, developmental cell 
death in Drosophila can be shown to be autophagy-dependent but independent of 
caspases (Denton et al., 2009). These examples show that developmentally 
programmed cell deaths can involve autophagy working alongside apoptosis, 
autophagy controlling apoptosis and autophagy working on its own with no involvement 
of the apoptosis machinery. 
Another example of a morphologically distinct form of autophagy-dependent cell 
death was identified called “autosis” (Liu et al., 2013), which was activated by an 
autophagy-inducing peptide and is modulated by widely used cardiac glycosides that 
target the Na+/K+-ATPase. This type of death may also occur in response to 
physiological signals because autosis was demonstrated to occur in a small population 
of cells (~1%) during nutrient starvation conditions and in vivo during hypoxic-ischemic 
injury in neonatal rats. The morphological features of autosis include nuclear 
convolution, increased autophagosomes, nuclear shrinkage, and focal perinuclear 
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swelling. Key experiments demonstrated that the inhibition of early autophagy 
abrogated Tat-Beclin 1-mediated cell death, and that this death does not require the 
canonical apoptosis or necroptotsis machinery. Interestingly, blocking 
autophagosome/lysosomal fusion with a late-stage autophagy inhibitor, bafilomycin A1, 
did not reduce the Tat-Beclin 1 death, suggesting that only the early steps of autophagy 
are required for this cell death mode. These sorts of distinctions—death modalities 
requiring early or late stage autophagy machinery—require consideration when 
developing autophagy inhibitors for patient use. It should be noted that there have been 
no subsequent studies describing autosis as a mode of cell death; more studies to 
understand the mechanisms and biological relevance of autosis are needed.  
Necrosis and autophagy 
 For many years, necrosis was regarded as an “accidental” process, but it is now 
understood that necrosis is often highly regulated and an intentional programmed 
mechanism. The most extensively studied form of programmed necrosis is called 
necroptosis, which is a form of programmed cell death dependent on receptor-
interacting Ser/Thr protein kinase 1 (RIPK1), RIPK3 and the pseudokinase MLKL. 
Necroptosis is best characterized by the stimulation of the TNFR1 (Tumor Necrosis 
Factor Receptor 1) by TNF resulting in the formation of different signaling complexes 
that create a “switch” leading to cell survival, apoptosis or necroptosis. The ubiquitin-
editing system and initiator caspases dictate the response to TNF ligand binding to 
TNFR. Complex I formation upon TNF binding consists of TNFR-associated death 
domain (TRADD), RIPK1, cellular inhibitor of apoptosis 1 (cIAP1), cIAP2, TNFR-
associated factor 2 (TRAF2) and TRAF5, leading to cell survival. Conversely, the 
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internalization of the TNFR1 and deubiquitylation of RIPK1 by the deubiquitylating 
enzyme cylindromatosis results in the formation of complex II, promoting either 
apoptosis or necroptosis. This complex consists of RIPK1, RIPK3, TRADD, caspase-8, 
and FAS-associated protein with a death domain (FADD). One result of complex II 
formation is the proteolytic cleavage of RIPK1 and RIPK3 by caspase-8, generating a 
pro-apoptotic caspase activation cascade. However, when caspase-8 is deleted or 
inhibited, complex II cannot produce apoptotic signals. Instead, RIPK1 and RIPK3 
phosphorylate each other, and aggregate in a complex called the necrosome. These 
autophosphorylation and transphosphorylation events recruit the mixed-lineage kinase 
domain-like (MLKL), which is itself phosphorylated by RIPK3. MLKL is then responsible 
for the permeabilization of the plasma membrane and death of the cell (Fuchs and 
Steller, 2015; Vandenabeele et al., 2010). A recent study found that the BH3-only pro-
apoptotic protein PUMA is transcriptionally activated, mediated by autocrine TNFα and 
enhanced NF-κB activity, in a RIP3/MLKL-dependent manner upon necroptosis 
induction. Upon induction, PUMA mediates the cytosolic release of mitochondrial DNA 
and activation of the cytosolic sensors DAI/Zbp1 and STING, resulting in enhanced 
phosphorylation of RIP3 and MLKL and a positive feedback loop (Chen et al., 2018).   
 The molecular determinants of a cell’s commitment to necroptosis are still being 
uncovered. A surprising study recently found that cancer cells can be targeted by 
activating caspase-independent cells death (CICD) (Giampazolias et al., 2017). When 
caspases are disengaged, permeabilization of the mitochondria does not lead to 
apoptosis but leads to the transcriptional upregulation of TNFα by NF-κB allowing for 
CICD/necroptosis to be activated. Consistent with previous literature, induction of 
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necroptosis in this work was induced by the production of TNFα in a manner that was 
dependent on activation of the transcription factor NF-κB. NF-κB was activated through 
the release of mitochondrial proteins such as SMAC (which accompany cytochrome c 
on MOMP), leading to the degradation of inhibitor of apoptosis proteins (IAPs) by the 
proteasome. IAP inhibition is known to cause stabilization of another kinase called NF-
κB-inducing kinase (NIK) and demonstrated that, when caspase activation is prevented, 
this mechanism occurs upon mitochondrial permeabilization leading to increased 
activity of NF-κB and subsequent increased expression of TNFα (Giampazolias et al., 
2017). It is important to delineate whether cancer cells die by necroptosis or apoptosis, 
as the type of cell death specifies whether or not the immune system is activated. 
Apoptosis is generally thought to be non-inflammatory, whereas necrotic types of cell 
death activate inflammatory responses (Green et al., 2009). This study provides a 
glimpse into how activating a specific type of cell death may have different outcomes in 
cancer therapy and human disease generally.  
Little is known about how autophagy is intertwined with necroptosis. However, 
some of the first evidence to show that autophagy could promote cell death came from 
a system that has gone on to become the best understood necroptosis pathway (Yu et 
al., 2004) and in this case, autophagy was shown to modulate these effects by 
selectively degrading the reactive oxygen species (ROS) scavenger enzyme, catalase 
(Yu et al., 2006). Bray et al provided another example of the coordination between 
necroptosis and autophagy (Bray et al., 2012). They found that concurrent mTOR 
inhibition by CCI-779 and inhibiting autophagosome maturation with chloroquine lead to 
the accumulation of autophagosomes that induced RIPK3-dependent and ROS-
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dependent necroptosis in renal cell carcinoma lines. Some evidence also implies that 
RIPK1 might be degraded by autophagy (Bray et al., 2012).  
As with formation of an apoptosis-inducing scaffold described above, evidence 
points to autophagosomal membranes acting as platforms for necrosome assembly, 
and serving as key sites to mediate necroptosis. Obatoclax, or GX15-070, is an indole 
bipyrrole compound that antagonizes Bcl-2, Bcl-XL, Bcl-w, and Mcl-1, and has been 
shown to activate autophagy and elicit non-apoptotic cell death in rhabdomyosarcoma 
cells. GX15-070-stimulated autophagy was linked to the assembly of the necrosome—
i.e. a complex involving FADD, RIPK1, and RIPK3—on autophagosomal membranes. 
ATG5 or ATG7 silencing mitigated this cell death, and co-immunoprecipitation studies 
suggest that GX15-070 stimulates an interaction between ATG5 and necrosome 
components. Further, RIPK1 knockdown or pharmacological inhibition of RIPK1 with 
necrostatin-1 blocked death by GX15-070 (Basit et al., 2013). Together, these data 
point to the formation of autophagosomes as key mediators for achieving efficient 
necrosome formation, resulting in necroptotic cell death by GX15-070.  
Studies from the Thorburn and Cramer laboratory (Goodall et al., 2016) show 
that mouse prostate cancer cells harboring a Map3k7 deletion and treated with TRAIL 
undergo necroptosis, not apoptosis, which is dependent on the ability of p62/SQSTM1 
to mediate necrosome assembly by RIPK1 recruitment. In the case where the assembly 
of the necrosome by p62/SQSTM1 is blocked, these cells will instead undergo 
apoptosis (Goodall et al., 2016). This provides additional evidence that autophagy can 
act as a scaffold to control cell death in addition to acting to degrade cargo. One of the 
implications of this study is that blocking autophagy at early steps of the pathway (e.g. 
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the formation of the autophagosome) versus blocking autophagy at later stages (e.g. 
the autophagosome-lysosome fusion step) can have differential effects on the cell death 
mode (Goodall et al., 2016). Overall, the above examples support the notion that 
autophagy can influence the fate of cells treated with compounds that induce 
necroptosis. While these examples are suggestive of important interactions between 
autophagy and the necroptosis machinery, more work is needed to uncover the 

























Experimental model and subject details 
Cell lines were maintained at 37°C and 5 % CO2 with media indicated in table 
below. The cells lines were authenticated at the Barbara Davis Center at University of 
Colorado—Anschutz Medical Campus. Six week old athymic nude mice were 
purchased and housed according to IACUC guidelines. See Table 2.1 for cell culture 
conditions.  
Clonogenic assay 
HCT116 cells were plated at 2000 cells per well of a 12-well plate. The next day, 
cells were treated with Nutlin-3a 20μM and/or chloroquine 40μM for 48 hours. These 
reagents were replenished after 24hrs. After 48 hours of exposure to the above 
reagents, full media was used to allow grow back for 7 days, replenishing media every 
72 hours. Cells were then fixed and stained with crystal violet. 
Chromatin immunoprecipitation 
HCT116 cells were plated at 40,000 cells/cm2 of a 150mm plate—40,000 X 
152 cm2= 6,080,000 per plate (3 plates per condition). The next day, cells were treated 
with bafilomycin 10 nM, Nutlin-3a 20μM, or chloroquine 40μM for 24 hours. Cells were 
then washed with PBS, fixed with a 1% formaldehyde/1x PBS solution for 15 minutes at 
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room temperature. The fixing reaction was stopped by the addition of 1 mL of 2.5 M 
glycine (0.125 M final). Cells were then washed 2X with cold PBS and harvested with 
RIPA buffer (150 mM NaCl, 1% v/v, Nonidet P-40, 0.5% w/v, deoxycholate, 0.1% w/v, 
SDS, 50mM EDTA, protease inhibitor cocktail, phosphatase inhibitor). Samples were 
then sonicated to generate <500 base pair DNA fragments. One mL of 1 mg/mL of 
protein lysate was precleared for 2 hours with 30μL of Protein A/G beads. FOXO3a CST 
75D8 (10 μL per IP) and RNA Polymerase II Clone H5 (20μL per IP) were used with 
60μL of Protein A/G beads, and inverted overnight at 4°C. Beads were pre-washed 
twice with PBS, then twice with RIPA buffer from above. For phosphorylated CTD of 
polymerase, immunocomplexes were recovered using anti-mouse IgM/protein A/G 
beads. Beads were washed twice with RIPA buffer, 4 times with IP buffer (100mM Tris 
HCl pH 8.5, 500mM LiCl, 1% v/v, Nonidet P-40, 1% w/v, deoxycholic acid), twice again 
with RIPA buffer, then twice with TE. Immunocomplexes were eluted at 65°C for 
10 minutes with 1% SDS. Reverse crosslinking was performed by adjusting to 200mM 
NaCl and incubated for 5hrs at 65°C. DNA was purified and then used in QPCR 
reaction. PCR primers used in these reactions are listed in the attached table. 
RT-QPCR 
RNA was isolated using Qiagen RNeasy kit following the manufacturer’s 
instructions. Reverse transcription reaction was performed using the Qiagen Quantitect 
RT kit according to manufacturer’s instructions. SYBR green CFX from Applied 
Biosystems was used in QPCR reactions with a standard curve ranging from 0.04 ng to 
50ng of cDNA. Quantities were calculated relative to this standard curve, and 
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normalized to 18s rRNA or GAPDH as housekeep gene control. Primers are listed in 
Table 2.2. 
Expression constructs, shRNAs, and transduction 
Protein depletion by shRNA was achieved by using the pLKO.1 system. These 
plasmids were obtained from the University of Colorado Functional Genomics Core. 
Lentiviruses were obtained by cotransfection of pLKO.1 shRNA plasmids with the 
lentiviral plasmids pMD2G, pRRE, and pRSV into HEK293FT using Mirus Transit LT1 
transfection reagent. Media was harvested at 48 and 72 hours post-transfection and 
stored at -80°C. Cells were plated at 30,000 cells per well of a 6-well plate and 1mL of 
virus used. Puromycin was used for selection (1 μg/mL). Sequences are listed in Table 
2.2. 
CRISPR/Cas9-mediated knock out 
For CRISPR/Cas9 knockout of ATG5 and ATG7, lentiviral constructs containing 
gRNAs targeting ATG5 and ATG7 (Table S1) were transduced into HCT116 cells as 
previously published (O'Prey et al., 2017). To avoid complications caused by clonal 
variation, ATG5 or ATG7 knockout cells from polyclonal populations were assayed by 
Western Blot for complete loss of protein expression and the polyclonal population used 
for functional tests. For CRISPR/Cas9 mediated knockout of the forkhead response 
element (FHRE), ribonuclear protein complexes (RNPs) were transfected into HCT116 
cells with Lipofectamine CRISPR Max based on previously published methods (Liang et 
al., 2015). Single cell clones were isolated and genomic DNA analyzed to determine 
whether the FHRE was mutated, then to minimize clonal variation, clones with 6 
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different mutated FHRE sequences were pooled and used for functional tests. 
Sequences of gRNAs are listed in Table 2.2. 
Immunoblots 
Western blotting was performed using standard methods with antibodies in 5% 
milk or 5% bovine serum albumin fraction V in TBST (0.1% Tween-20). Proteins were 
separated on SDS-PAGE 1.0mm mini gels and transferred to nitrocellulose or PVDF 
membranes. Blots were then probed with antibodies diluted as above. Semi-dry transfer 
apparatus was run at 15V for 70 minutes. Antibodies are listed in Table 2.3. 
Fluorescence microscopy 
Lentiviral plasmid pBABE puro mCherry-eGFP-HA-FOXO3a was cloned by 
digesting pBABE puro mCherry-eGFP-LC3 with MfeI and SalI, and ligating FOXO3a 
cDNA generated from AddGene plasmid #1787 (HA-FOXO3a). Sequences are listed in 
Table 2.2. Lentiviral transduction of this construct into MCF7, MCF10a, and HCT116 
was performed, expressed for 72hrs to reach steady-state, and imaged. Live cells were 
plated at 2,000 cells and imaged in MatTek 35mm glass bottom culture dishes using a 
confocal laser scanning Olympus FV1000 with a 60X objective. LysoTracker was used 
at concentration of 0.5μM. 
Incucyte cell imaging 
Cells were plated in 96-well plates at 3,000 cells/well. After cell attachment 
(48hrs), cells were treated with indicated concentrations of Nutlin-3a, chloroquine, 
bafilomycin A1, or staurosporine. CellEvent Green Caspase-3/7 reagent was from 
Invitrogen C10423 (used at 5μM final concentration). Sytox Green (Invitrogen S7020) 
cell dye reagent was used at 50nM. Images were taken using the Incucyte Zoom 
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system every 4hrs using a 4X objective. Results are displayed normalized to the cell 
number and the initial time point (time point zero). 
In vivo tumor studies 
Six week old athymic nude mice were purchased and housed according to 
IACUC guidelines. Two million HCT116 parental or ΔFHRE cells were counted using 
the Vi-cell (Beckman Coulter) resuspended, on ice, in 100μL of 0.2% matrigel:PBS (1:1) 
and injected into each flank using 28g needles. Mice were anesthetized using 
isoflurane. Dosing of Nutlin-3a and chloroquine began when 80% of the mice had 
tumors that were ≥100mm3. Mice were given oral gavage (28g needles, 38mm long) 
twice daily of Nutlin-3a (Selleckchem—S1061) at 200 mg/kg—a 20 mg/mL stock was 
formulated in 2% Klucel (Hydroxypropyl cellulose—AlfaAesar) and 0.5% Tween 80 
(Fischer BP338-500) in PBS. Mice were also given intraperitoneal injections once daily 
of chloroquine diphosphate (MPBio—193919) at 60 mg/kg—a 6 mg/mL stock was 
formulated in PBS. Tumor volume was measured and calculated regularly (roughly 
every other day) using a Sylvac-Fowler Bluetooth S_cal EVO caliper. Mice were 
sacrificed when tumor volume reached 200mm3, or a combined tumor burden per 
mouse of 300mm3. Mice were sacrificed by CO2 followed by cervical dislocation 
according to IACUC protocol and tumors were harvested for RNA and protein. Tumor 
samples were homogenized and processed for RNA using above methods for RT-
QPCR analysis. 
Optogenetic autophagy manipulation 
Experiments were performed with a LofTek ultraviolet 395nm LED handheld 
flashlight mounted in an aluminum foil-lined cardboard box. Cells were exposed to the 
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LED for 5 or 10 minutes with continuous light, and all experiments were controlled to 
account for any light-associated cell toxicity (all experiments were normalized to toxicity 
associated with parental cells not expressing the ASAP construct, or to an ASAP control 
plasmid—these control conditions were exposed to the same amount of light as the 
experimental condition). Cells were centered within the LED box to allow for direct 
incidence with the LED; each plate was photoactivated separately to ensure equal and 
proper LED exposure. Following LED exposure, cells were immediately returned to the 
cell culture incubator and incubated for indicated durations, followed by collection with 
stringent RIPA buffer (150 mM NaCl, 1% v/v, Nonidet P-40, 0.5% w/v, deoxycholate, 
0.1% w/v, SDS, 50mM EDTA, protease inhibitor cocktail, phosphatase inhibitor). 
Quantification and statistical analysis 
Data are presented as means ± standard errors of the mean (SEMs) as indicated 
within each figure legend. Independently prepared samples from at least two 
experiments, displayed as circles, squares or triangles, are displayed on column 
graphs. One-way analyses of variance (ANOVA), two-way analyses of variance, or 
unpaired Student’s t-tests were performed where indicated in figure legends using 








Table 2.1  
Cell culture conditions—All cell lines authenticated via University of Colorado—
Anschutz Medical Campus Barbara Davis Center 
Line Medium Serum Additives 
MCF7 DMEM high glucose 10% FBS L-glutamine, insulin, Pen/Strep 
293T DMEM high glucose 10% FBS Pen/Strep 
MCF10A DMEM/F12 5% HS 
insulin, hydrocortisone, EGF, cholera toxin, 
Pen/Strep 








insulin, hydrocortisone, EGF, cholera toxin, L-
glutamine, Pen/Strep 
BT-549 RPMI 10% FBS L-glutamine, Pen/Strep, Insulin 
MEF DMEM high glucose 10% FBS Pen/Strep 
HT1080 MEM 10% FBS Sodium pyruvate, NEAA, Pen/Strep 
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Table 2.2  
ChIP-QPCR, RT-QPCR, QPCR primers, gRNAs, and shRNAs  
ChIP Primers Source 
BBC3 -4,868 FW 
ACTGTGTGCCTAGCCCAATG 
This paper 
BBC3 -4,868 RV   
ACAGCACAGGTCCCTACCTC 
This paper 
BBC3 -2,948 FW   
AGGTGTGAGGTACAGGTGGGACC 
This paper 
BBC3 -2,948 RV   
CCTGTTGCTTGACACTGATGAAGTTGA 
This paper 
BBC3 -1,460 FW   
CACACCATACACCTAAAAAGAGTGA 
This paper 
BBC3 -1,460 RV   
ATCCCAACCAACTTGCGCTT 
This paper 
BBC3 +2,042 FW   
CAGGGTCGCCGGGTGAGAGG 
This paper 
BBC3 +2,042 RV   
CGAGCCCGCACCCCATTGTTT 
This paper 
BBC3 +8,165 FW   
CAGGGTCTCACTGTCTCCCAG 
This paper 




BBC3 +9,137 FW   
GGTGGTCCCCACTTAGCACA 
This paper 





Table 2.2 Continued. 
ChIP-QPCR, RT-QPCR, QPCR primers, gRNAs, and shRNAs  
 












BBC3 +14,888 RV   
GATGGTTTTGTGCATTGCCAG 
This paper 
gDNA PCR to BBC3 FHRE FW  ACACCGCGCCTCTCCAAACCCCGCGA This paper 
gDNA PCR to BBC3 FHRE RV  AAACTCGGAGCCAGACACGCGCACACACCCA This paper 




RT-QPCR Primers This paper 
BBC3 QPCR FW   
TCAACGCACAGTACGAGCG 
This paper 
BBC3 QPCR RV   
AAGGGCAGGAGTCCCATGAT 
This paper 
18S QPCR FW   
GCCGCTAGAGGTGAAATTCTTG 
This paper 
18S QPCR RV   
CTTTCGCTCTGGTCCGTCTT 
This paper 
GAPDH QPCR FW   
CGTGGAAGGACTCATGACCA 
This paper 





Table 2.2 Continued 
ChIP-QPCR, RT-QPCR, QPCR primers, gRNAs, and shRNAs 
 
FOXO3a QPCR RV   
GGGCTTTTCCGCTCTTCCCCC 
This paper 

























FW: ATGGACGCAGCTACTCTGA  
RV: AGTATCCAAACGGGCTCTGA 
This paper 
gRNA Sequences  
gRNA CRISPR-Cas9 to BBC3 FHRE FW  GCGGGTTTGTTTACAA   This paper 
gRNA CRISPR-Cas9 to BBC3 FHRE RV  TTGTTTGTAAACAAACCCGC This paper 
gRNA CRISPR-Cas9 to BBC3 FHRE FW  GGGTTTGTTTACAAACAATG   This paper 
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Table 2.2 Continued 
ChIP-QPCR, RT-QPCR, QPCR primers, gRNAs, and shRNAs 
 
gRNA CRISPR-Cas9 to BBC3 FHRE RV   
CATTGTTTGTAAACAAACCC 
This paper 
gRNA CRISPR-Cas9 to NTC  GTAGCGAACGTGTCCGGCGT This paper 
gRNA CRISPR-Cas9 to ATG5  AAGAGTAAGTTATTTGACGT This paper 
gRNA CRISPR-Cas9 to ATG7  GAAGCTGAACGAGTATCGGC O’Prey et al 2017 
Sub-cloning Primers O’Prey et al 2017 
HA-FOXO3 into pBABE puro mCherry-GFP in place of LC3 via MfeI (comp. cohesive 
end of EcoRI) and SalI.  
(digest vector with EcoRI and SalI, but digest 












pBABE puro Tom20TS-PhoCL-3xmyc-STX17deltaNTD (ASAP) via Gibson Assembly 













6. ggtcgaccactgtgctggcgTTAACTGCATTTCTTGTCAG  
This paper 
 
pBABE puro Tom20TS-PhoCL-3xmyc (ASAP Control) via restriction site cloning in 
BamHI and EcoRI 









Table 2.2 Continued 
ChIP-QPCR, RT-QPCR, QPCR primers, gRNAs, and shRNAs  
 











pCW57.1 Tet-inducible STX17deltaNTD (STX17 Dominant Negative) via Gateway 






shRNA Target Sequence: This paper 
pLKO.1 human shATG7 ID TRCN0000007587  
CCGGCCCAGCTATTGGAACACTGTACTCGAGTACAGTGTTCCAATAGCTGGGTTTT 
This paper 




pLKO.1 human shFKHRL1 (FOXO3a) ID TRCN0000235488 
CCGGGGACAATAGCAACAAGTATACCTCGAGGTATACTTGTTGCTATTGTCCTTTTT 
Thorburn et al 2013 
pLKO.1 human shFKHRL1 (FOXO3a) ID TRCN0000010334  
CCGGACAATAGCAACAAGTATACCCTCGAGGGTATACTTGTTGCTATTGTCTTTTTG 
Thorburn et al 2013 
pLKO.1 human shPIK3C3 (VPS34) ID TRCN0000196840   
GAGATGTACTTGAACGTAATG 
Thorburn et al 2013 
pLKO.1 human shULK1 ID TRCN0000199801  
CCGGGCGCCTGTTCTACGAGAAGAACTCGAGTTCTTCTCGTAGAACAGGCGCTTTT
TTG 





Key Resources Table 
Key Resources Table 
  
Antibodies                                                                                       Source                      Identifier 
































Rabbit polyclonal LC3 Novus Cat# NB100-2220, 
RRID:AB_10003146 
 
Mouse monoclonal beta-Actin  
 
Sigma-Aldrich Cat# A5441, 
RRID:AB_476744 
 
Mouse monoclonal p62/SQSTM1 Novus Cat# H00008878-M01, 
RRID:AB_548364 
 
Mouse monoclonal Purified anti-RNA Polymerase II RPB1 
antibody Clone H5 (Used for ChIP) 
 
Biolegend Cat# 920204, 
RRID:AB_2616695 
  
Chemicals, Peptides, and Recombinant Proteins 
Bafilomycin A1 Sigma-Aldrich B1792; CAS RN: 88899-
55-2  
 
Chloroquine  MP Biomedicals 93919; CAS RN: 50-63-5 
 
Nutlin-3a Cayman Chemicals 10004372; CAS RN: 
548472-68-0 
 
Protease inhibitor cocktail Roche 11836153001 
 
Phosphatase inhibitor Sigma-Aldrich P5726 
Protein A/G Plus beads Santa Cruz SC-2003 
Commercial Assays 
Qiagen RNeasy RNA isolation kit Qiagen Cat# 74104 
 










Table 2.3 Continued  
 
Key Resources Table 
 
   Oligonucleotides 
See Table 2.2 for ChIP primers   
See Table 2.2 for QPCR primers   
See Table 2.2 for gRNAs   
See Table 2.2 for sub-cloning primers   
See Table 2.2 for shRNA targeting sequences   
Recombinant DNA 
pBABE puro mCherry-GFP-HA-FOXO3a This paper and 
Addgene x 2  
#1787 and #1764 
See Table 2.2 for additional sub-cloning info   
Reagent Catalog Numbers: 
SYBR Green CFX for QPCR Applied biosystems 4472942 
Mirus Transit LT1 transfection reagent Mirus MIR2304 
CRISPR Max  ThermoFisher CMAX00001 
Cell Event Caspase 3/7 Invitrogen C10423 
 
MatTek 35mm dishes for living imaging MatTek P35GC-1.5-14-C 
LysoTracker Blue DND-22 ThermoFisher Cat# L7525 
 Incucyte ZOOM imaging system Essen BioScience N/A 
LofTek ultraviolet 395nm LED handheld flashlight   
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CHAPTER III 
AUTOPHAGY INHIBITION INCREASES PUMA TRANSCRIPTION VIA FOXO3A 3 4 
Introduction 
Autophagy is the mechanism by which cellular material is delivered to lysosomes 
via double membrane vesicles called autophagosomes. Although autophagy’s ability to 
protect against apoptosis is well established, the molecular machinery that links 
autophagy and apoptosis to govern cell-fate decisions is poorly understood (Fitzwalter 
and Thorburn, 2015a).  
The Thorburn laboratory previously reported (Thorburn et al., 2014) that the pro-
apoptotic protein PUMA (p53-upregulated modulator of apoptosis, also known as BBC3) 
is increased upon autophagy inhibition. This increase is not sufficient to cause cells to 
die on their own but can sensitize them to an apoptosis inducer. Here, I investigated the 
underlying mechanism by which this occurs revealing a transcriptional feedback loop 
that links basal autophagy homeostasis to apoptosis sensitivity. I found that the ability of 
the Forkhead Box transcription factor FOXO3a to bind to the PUMA gene is necessary 
to upregulate PUMA levels upon genetic or pharmacological autophagy inhibition. 
                                                 
 
3 Portions of this chapter were published with permission from Developmental Cell: 
Autophagy Inhibition Mediates Apoptosis Sensitization in Cancer Therapy by Relieving 
FOXO3a Turnover. 
Fitzwalter et al., 2018, Developmental Cell 44, 555–565 March 12, 2018, Elsevier Inc. 
https://doi.org/10.1016/j.devcel.2018.02.014  
 
4 Portions of this chapter were published with permission from Autophagy: 
FOXO3 links autophagy to apoptosis, Autophagy, 14:8, 1467-1468, DOI: 
10.1080/15548627.2018.1475819 
Brent E. Fitzwalter & Andrew Thorburn 
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Further, I show that FOXO3a is selectively regulated by autophagic turnover to regulate 
its transcriptional activity. 
Results 
Previous work demonstrated that shRNA knockdown of essential autophagy 
regulators or pharmacological inhibition of autophagy caused higher PUMA protein 
levels (Thorburn et al., 2014). A simple explanation for this effect would be that PUMA 
protein is degraded by autophagy. However, inhibition of autophagy by knockdown of 
multiple autophagy regulators including, ATG7, PIK3C3/Vps34, and ULK1 (Unc-51-like 
Autophagy Activating Kinase 1) caused increased PUMA mRNA levels in HCT116 
colorectal cancer cells (Figures 3.1a-c) as well as other cancer cell lines including HeLa 
and MCF7 (Figures 3.1d-e). An increase in PUMA mRNA levels was also observed 
when two essential autophagy regulators ATG7 or ATG5 were knocked out using 
CRISPR/Cas9 (Figure 3.2a). Treatment with bafilomycin A1, an inhibitor of vacuolar-
type H+-ATPase that blocks autophagy by preventing lysosomal acidification also 
caused increases in PUMA mRNA (Figure 3.2b), and this was abolished following drug 
washout (Figure 3.2c). PUMA is a well-known target gene for p53 however, basal 
autophagy inhibition in HCT116 cells that lack p53 displayed similar increases in PUMA 
mRNA compared to HCT116 wild-type cells (Figure 3.2d). To test if autophagy inhibition 
causes increased PUMA gene transcription, chromatin immunoprecipitation (ChIP) was 
performed at the PUMA locus using an antibody that recognizes elongating RNA 
Polymerase II (Komarnitsky et al., 2000). Autophagy inhibition with bafilomycin A1 
(Figure 3.3a) or chloroquine (Figure 3.3b) caused enrichment of active RNA Pol II 







Autophagy inhibition increases PUMA mRNA levels in multiple cancer cell lines
48
Figure 3.1
Autophagy inhibition increases PUMA mRNA levels in multiple cancer cell lines
(a-e) HCT116, HeLa, or MCF7 cells were transduced with lentiviral shRNAs targeting 
autophagy regulators (shATG7, shVps34, and shULK1) or shCtrl, and the resulting 





Autophagy gene knockout or pharmacological autophagy inhibition increases 
PUMA mRNA levels, independent of p53.
(a) HCT116 cells were transduced with a lentiviral CRISPR/Cas9 plasmid targeting 
ATG5, ATG7, or a non-targeting control, and BBC3 (PUMA) mRNA levels were 
measured relative to 18S rRNA control. 
(b) HCT116 cells were treated with vehicle or bafilomycin A1 10 nM, an autophagy 
inhibitor, for 24 hr and BBC3 (PUMA) mRNA levels were measured relative to 18S rRNA
control.
(c) HCT116 cells treated with bafilomycin 10 nM for 24 hr, then washed out for 16 and 
24 hr. BBC3 (PUMA) mRNA levels were measured relative to 18S rRNA control.
(d) HCT116 cells or HCT116 p53 -/- cells were treated with vehicle or bafilomycin A1 10 
nM, an autophagy inhibitor, for 24 hr, and BBC3 (PUMA) mRNA levels were measured 






Autophagy inhibition causes increased PUMA transcription similar to other 
stimuli that active PUMA.
(a) Chromatin immunoprecipitation (ChIP) analysis in HCT116 cells of RNA polymerase 
II phosphoserine 2 (indicative of active, elongating RNA Pol II) occupancy at the 
BBC3/PUMA genomic locus relative to IgM control with vehicle or bafilomycin A1 10 nM
treatment, an autophagy inhibitor, for 24 hr.
(b) Chromatin immunoprecipitation analysis of RNA polymerase II phospho serine 2 
(indicative of active, elongating RNA pol II) occupancy in HCT116 cells
at the BBC3 (PUMA) genomic locus relative to IgM control with vehicle or chloroquine 
40μM treatment for 24hrs.
(c) Chromatin immunoprecipitation analysis in HCT116 cells of RNA polymerase II 
phospho serine 2 (indicative of active, elongating RNA pol II)
occupancy at the BBC3 genomic locus relative to IgM control with vehicle or Nutlin-3a 
20μM treatment for 24hrs
51
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transcription (Figure 3.3c). Taken together, these data indicate that basal autophagy 
inhibition leads to increased PUMA mRNA transcription in a p53-independent manner.  
The basal rate of autophagy is regulated by several transcription factors (Feng et 
al., 2015; Füllgrabe et al., 2014) including FOXO3a, which is critical for maintenance of 
a gene expression program that allows autophagy to protect hematopoietic stem cells 
from cytokine deprivation (Warr et al., 2013b). Additionally, FOXO3a can regulate 
PUMA expression (Amente et al., 2011; You et al., 2006) leading us to hypothesize that 
FOXO3a might be responsible for increased PUMA expression upon autophagy 
inhibition. In support of this idea, bafilomycin A1 failed to increase PUMA mRNA when 
FOXO3a was knocked down via shRNA (Figure 3.4a) or knocked out with 
CRISPR/Cas9 (Figures 3.4b). ChIP analysis revealed that FOXO3a displays a 
constitutive level of occupancy at the PUMA locus in an intronic region containing a 
Forkhead Response Element (FHRE) +1,902 basepairs downstream of the 
transcriptional start site as was previously reported (Eijkelenboom et al., 2013). Upon 
basal autophagy inhibition with bafilomycin A1, FOXO3a became enriched 
approximately 20-fold over IgG control at this site (Figures 3.4c). Mutation of the 
FOXO3a-binding FHRE in the PUMA locus using CRISPR/Cas9 gene editing to create 
a set of three pooled HCT116 clones each with deletions in the FHRE (Figure 3.4d) was 
sufficient to block the increase in PUMA expression upon pharmacological (Figure 
3.4e). These data indicate that inhibition of basal autophagy results in increased 
FOXO3a-driven transcription of the PUMA gene through a single transcription factor 









FOXO3a binding to the BBC3/PUMA locus is necessary for PUMA transcriptional 
activation.
(a) Left: HCT116 p53-/- cells were transduced with two different lentiviral shRNAs
targeting FOXO3a transcripts. After 24 hr of vehicle or bafilomycin A1 10 nM treatment, 
PUMA mRNA levels were measured relative to 18S rRNA control. Right: western blot 
showing FOXO3a protein levels after treatment with two independent shRNAs targeting 
FOXO3a or shCtrl
(b) Parental or FOXO3a-/- pooled HCT116 cells were treated with bafilomycin A1 10 nM, 
an autophagy inhibitor, for 24 hr, and BBC3 (PUMA) mRNA levels were measured 
relative to GAPDH control 
(c) ChIP analysis in HCT116 cells of FOXO3a occupancy at the BBC3/PUMA genomic 
locus relative to IgG control or treatment with vehicle or 10 nM bafilomycin A1, an 
autophagy inhibitor, for 24 hr. The x axis indicates the probed position along the 
BBC3/PUMA locus relative to the transcriptional start site. The BBC3/ PUMA locus 
schematic is not to scale; stars indicate the approximate position of each amplicon..
(d) Sequencing alignments showing ΔForkhead Response Element (ΔFHRE) deletions 
in HCT116 cells at the BBC3/PUMA locus at position +1,902 relative to the 
transcriptional start site using CRISPR/Cas9 targeting. Blue and green base pairs 
indicate FHRE. Multiple clones were obtained with homozygous indels and were pooled 
to limit clonal variation. 
(e) HCT116 parental or ΔFHRE cells were treated for 24 hr with vehicle or 10 nM
bafilomycin A1, an autophagy inhibitor, and BBC3 (PUMA) mRNA levels were measured
relative to 18S rRNA control.
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Multiple FOXO3a-/- clones were obtained by CRISPR/Cas9-mediated knockout 
(Figure 3.5a). FOXO3a occupancy at the PUMA locus had a basal level of 
approximately 10-fold over an IgG control, but increased to 15-fold upon treatment with 
chloroquine (Figure 3.5b). HCT116 cells lacking a FHRE were unable to upregulate 
PUMA mRNA levels upon genetic knockdown of ATG7 (Figure 3.5c), but were still able 
to upregulate PUMA upon treatment with Nutlin-3a (Figure 3.5d). FOXO3a had a 
constitutive level of occupancy at the BIM locus that increased nearly two-fold with 
bafilomycin A1 treatment for 24hrs (Figure 3.5e), but FOXO3a occupancy at non-
apoptotic proteins like SOD2 did not change with autophagy inhibition at that time point 
(Figure 3.5f). Pharmacological or genetic autophagy inhibition by CRISPR/Cas9 
knockout of essential autophagy genes resulted in higher BIM mRNA levels (Figures 
3.5g-h). Several other known FOXO3a target genes including non-apoptotic genes were 
also activated (albeit with varying kinetics) upon bafilomycin A1 treatment (Figure 3.5i 
and Figures 3.6a-d). These data suggest that FOXO3a increases its transcriptional 
activity at multiple gene targets upon genetic or pharmacological autophagy inhibition.  
FOXO3a is degraded by the proteasome in response to various signaling events 
(Huang and Tindall, 2011) but it is not known if autophagy also regulates FOXO3a. To 
test this and determine if autophagy-mediated turnover of FOXO3a explains how 
autophagy inhibition can enhance FOXO3a transcriptional activity, HCT116 cells were 
treated with bafilomycin A1 (Figures 3.7a), resulting in a time-dependent increase in the 
amount of FOXO3a protein indicating that basal FOXO3a turnover can occur via the 
lysosome. Consistent with this turnover being due to (macro)autophagy, HCT116 cells 





































































































































































































































































































































































































































FOXO3a and the Forkhead Response Element are necessary for PUMA 
upregulation following autophagy inhibition, and FOXO3a binds to other FOXO3a 





FOXO3a and the Forkhead Response Element are necessary for PUMA 
upregulation following autophagy inhibition, and FOXO3a binds to other FOXO3a 
targets upon autophagy inhibition. 
(a) Western blot analysis of FOXO3a protein levels in HCT116 clones targeted with 
CRISPR/Cas9 using recombinant Cas9 and gRNAs. These clones were pooled to limit 
monoclonal variation.
(b) Chromatin immunoprecipitation analysis in HCT116 cells of FOXO3a occupancy at 
the BBC3 (PUMA) genomic locus relative to IgG control with vehicle or chloroquine 
40μM for 24hrs. 
(c) Parental or ∆FHRE HCT116 cells were transduced with lentiviral shCtrl or shATG7 
and PUMA mRNA levels were measured relative to an 18s rRNA control.
(d) HCT116 ∆FHRE cells that lack the ability to bind FOXO3a in the BBC3 (PUMA) 
locus were treated with Nutlin-3a 20μM for 24hrs and PUMA mRNA levels were 
measured relative to 18S rRNA control.
(e) Chromatin immunoprecipitation analysis in HCT116 cells of FOXO3a occupancy at 
the BIM genomic locus relative to IgG control with vehicle or bafilomycin A1 10nM for 
24hrs.
(f) Chromatin immunoprecipitation analysis in HCT116 cells of FOXO3a occupancy at 
the SOD2 genomic locus relative to IgG control with vehicle or bafilomycin A1 10nM for 
24hrs.
(g) HCT116 cells treated with bafilomycin A1 10nM for indicated duration and BIM 
mRNA levels were measured relative to 18S rRNA control.
(h) HCT116 cells were transduced with a lentiviral CRISPR/Cas9 plasmid targeting 
ATG5, ATG7, or a non-targeting control and BIM mRNA
levels were measured relative to 18s rRNA control.
(i) HCT116 cells treated with bafilomycin A1 10nM for indicated duration and SOD2 






















































































































Other FOXO3a targets are upregulated upon pharmacological autophagy 
inhibition
(a) HCT116 cells treated with bafilomycin A1 10nM for indicated duration and SESN1 
mRNA levels were measured relative to 18S rRNA loading control.
(b) HCT116 cells treated with bafilomycin A1 10nM for indicated duration and Prkaa2 
mRNA levels were measured relative to 18S rRNA loading control.
(c) HCT116 cells treated with bafilomycin A1 10nM for indicated duration and BNIP3 
mRNA levels were measured relative to 18S rRNA loading control.
(d) HCT116 cells treated with bafilomycin A1 10nM for indicated duration and BNIP3L 














FOXO3a is a substrate for basal autophagy
(a) HCT116 cells treated with 10 nM bafilomycin A1, an autophagy inhibitor, for the 
indicated duration. Whole-cell lysates were probed for FOXO3a protein levels. 
(b) HCT116 cells were transduced with lentiviral constructs containing Cas9 and gRNA 
targeting ATG5, ATG7, or a non-targeting control, and whole-cell lysates were probed for 
indicated proteins. 
(c) HCT116 cells were transduced with lentiviral shRNAs targeting p62/SQSTM1 or 
shCtrl and probed for indicated proteins.
(d) Western blot analysis on whole-cell lysates of HCT116 cells expressing mCherry-
GFP-FOXO3a treated with 10 nM bafilomycin A1, an autophagy inhibitor, for 8 hr. 
(e) Western blot analysis of whole-cell lysates of HCT116 cells expressing mCherry-
GFP-FOXO3a transduced with shCtrl or shp62/SQSTM1 lentivirus.
(f) Schematic representation of expression construct and how it was used to understand 
the environment of FOXO3a localization. 
(g) Confocal images of HCT116 cells expressing mCherry-GFP-FOXO3a and treated 
with a lysosomal dye. White arrows indicate regions of interest where FOXO3a resides 
in an acidic compartment. 
(h) Confocal images of HCT116 cells expressing mCherry-GFP-FOXO3a transduced 
with shRNA targeting ATG5.
(i) Confocal images of HCT116 cells expressing mCherry-GFP-FOXO3a transduced 
with shRNA targeting ATG7. 
(j) Confocal images of HCT116 cells expressing mCherry-GFP-FOXO3a treated with 10 
nM bafilomycin A1, an autophagy inhibitor, for 8 hr.
Scale bars, 10 µm. 
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knockout showed a robust increase in FOXO3a protein compared to control cells 
(Figure 3.7b). Additionally, shRNA knockdown targeting p62/SQSTM1, a protein that 
recruits substrates to the autophagosome, also increased FOXO3a protein HCT116 
cells (Figures 3.7c). Exogenously expressed FOXO3a protein also increased when cells 
were treated with bafilomycin A1 (Figure 3.7d) or p62/SQSTM1 shRNA (Figure 3.7e).  
If FOXO3a is a substrate for autophagy, it should localize to autophagosomes 
and lysosomes. To test this, I expressed a construct expressing mCherry-eGFP-
FOXO3a (Figure 3.7f). eGFP fluorescence, but not mCherry, is sensitive to decreased 
pH and this provides a basis to monitor autophagosome and autolysosome targeting of 
autophagy markers such as LC3B (Gump et al., 2014; Kimura et al., 2007) and 
autophagy cargos (Dou et al., 2015) . If FOXO3a is in a pH-neutral environment, such 
as the cytoplasm or nucleus, both eGFP and mCherry should fluoresce resulting in a 
diffuse yellow signal from the overlayed mCherry and eGFP. If FOXO3a is concentrated 
into a small pH neutral environment, like an autophagosome, I expect a punctate yellow 
signal and, if FOXO3a resides in an acidic environment, such as an autolysosome, I 
should see punctate red signals from the overlayed mCherry and the quenched eGFP 
fluorescent signals (Figure 3.7f). HCT116 cells expressing the mCherry-eGFP-FOXO3a 
protein under basal conditions showed a significant amount of FOXO3a localized to 
acidic compartments that were also positively stained by a lysosomal marker (Figures 
3.7g). Upon shRNA knockdown of ATG5 or ATG7 (Figures 3.7h-i) or blocking lysosomal 
acidification with bafilomycin A1 (Figure 3.7j), the predominance of punctate red signal 
was reverted to yellow and FOXO3a accumulated in the nucleus consistent with the 
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data above showing that FOXO3a binds to and transactivates the PUMA locus and 
causes new transcription upon autophagy inhibition.  
The above results were also observed in other cell lines that are tumorigenic and 
non-tumorigenic. MCF7 cells treated with bafilomycin A1 (Figure 3.8a) or chloroquine 
(Figure 3.8b-c) showed an increase in FOXO3a protein levels. FOXO3a mRNA levels 
did not change upon genetic deletion of the autophagy genes ATG5 or ATG7 (Figure 
3.8d). ATG7 shRNA knockdown also caused a robust increase in FOXO3a protein 
compared to shCtrl cells (Figure 3.8e) and with p62/SQSTM1 shRNA knockdown 
(Figure 3.8f-g), without increased FOXO3a mRNA (Figure 3.8h). Importantly, shRNA 
targeting of another autophagy receptor that recruits cargo to the autophagosome, 
NBR1, did not cause an increase in FOXO3a protein (Figure 3.8i). 
Using the construct described above, I determined that FOXO3a is a substrate 
for basal autophagy in multiple cells lines, including MCF7 (Figure 3.9a) and MCF10a 
(Figure 3.9b), and quantified the amount of lysosomal-targeted FOXO3a puncta 
(Figures 3.9c-d) 
These data indicate that FOXO3a is targeted to autolysosomes allowing 
FOXO3a levels to be controlled by basal autophagy in addition to the proteasome as 
previously identified (Huang and Tindall, 2011). These data support a model whereby a 
transcription factor that controls autophagy is itself degraded by autophagy and, when 

































































































































































































Autophagy regulates FOXO3a protein levels, but not mRNA levels in different 
tumor cells
(a) MCF7 cells were treated with vehicle or bafilomycin A1 10nM and probed for 
FOXO3a protein levels. 
(b) MCF7 cells were treated with vehicle or chloroquine 40μM and probed for FOXO3a 
protein levels.
(c) MCF7 or MCF10a cells were treated with vehicle or chloroquine 40μM for 2 or 4 
hours and probed for FOXO3a protein levels. 
(d) HCT116 cells transduced with lentiviral constructs containing Cas9 and gRNA 
targeting ATG5, ATG7, or a non-targeting control and FOXO3a mRNA levels were 
measured relative to 18s rRNA control.
(e) MCF7 cells were transduced with lentiviral shRNAs targeting autophagy transcript 
shATG7 or shCtrl scrambles. FOXO3a protein levels are shown in the presence or 
absence of ATG7 shRNA knockdown.
(f) MCF7 cells were transduced with lentiviral shRNAs targeting autophagy transcript 
shp62/SQSTM1 or shCtrl scrambles. FOXO3a protein levels are shown in the presence 
or absence of p62/SQSTM1 shRNA knockdown.
(g) MCF10a cells were transduced with lentiviral shRNAs targeting autophagy transcript 
shp62/SQSTM1 or shCtrl scrambles. FOXO3a protein levels are shown in the presence 
or absence of shp62/SQSTM1 shRNA knockdown.
(h) HCT116 cells were transduced with lentiviral shRNAs targeting p62/SQSTM1 or 
shCtrl, and FOXO3a mRNA levels were measured relative to 18s rRNA control.
(i) HCT116 cells were transduced with lentiviral shRNAs targeting NBR1 or shCtrl
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FOXO3a is substrate for basal autophagy in both cancer cells and non-
tumorigenic cells
(a) Confocal images of MCF7 cells expressing mCherry-GFP-FOXO3a treated with a 
lysosomal dye. 
(b) Confocal images of MCF10a cells expressing mCherry-GFP-FOXO3a treated with a 
lysosomal dye.
(c) Quantitation of lysosomal FOXO3a puncta per cell in MCF7 cells.
(d) Quantitation of lysosomal FOXO3a puncta per cell in MCF10a cells. 




 Upon genetic or pharmacological autophagy inhibition, the levels of the pro-
apoptotic protein PUMA increase. Surprisingly, the obvious mechanism for such an 
effect – i.e., PUMA protein is degraded by selective autophagy – does not apply. 
Instead, PUMA is actively transcribed upon autophagy inhibition by the Forkhead Box 
transcription factor FOXO3a, which upregulates the BBC3 gene via a single forkhead 
response element (FHRE) in an intron. CRISPR/Cas9-mediated deletion of this FHRE 
in the endogenous BBC3 locus is sufficient to block PUMA upregulation upon 
autophagy inhibition. As I will show in the next Chapter, mutating a single transcription 
factor binding site in the intron of the PUMA gene is able to completely reverse the 
apoptosis sensitization conferred by inhibiting autophagy.  
FOXO3a poises cells for rapid induction of autophagy following cytokine 
deprivation (Warr et al., 2013a). And, like some other transcription factors, it does so by 
transactivating autophagy-related genes. I wondered how the FOXO3a transcription 
factor is regulated so as to increase its activity upon autophagy inhibition. I found that 
FOXO3a is itself a substrate for basal autophagic degradation, and when this is blocked 
by either pharmacological autophagy inhibitors or by inactivation of autophagy 
regulators such as ATG5 or ATG7, then FOXO3a translocates to the nucleus where it 
can activate target genes. This finding adds another interesting feature to the 
mechanism I uncovered; FOXO3a – a transcription factor that regulates autophagy – is 
itself regulated by autophagic degradation. This suggests that FOXO3a is at the center 
of a homeostatic feedback loop to correct autophagy perturbations by transactivating 
autophagy targets when basal autophagy is inhibited. However, if autophagy inhibition 
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persists, then the cell also activates pro-apoptotic genes such as PUMA via the same 
transcription factor and thus becomes sensitized to undergo cell death. I therefore 
propose that basal autophagic turnover of FOXO3a serves as a surveillance 
mechanism to detect and correct autophagy flux disruptions. As I will show in the next 
Chapter, this mechanism is important ensure that those cells where autophagy is 
deficient, are primed to undergo apoptosis.  
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AUTOPHAGY REGULATION OF PUMA EXPRESSION VIA FOXO3A CAN BE 
LEVERAGED TO IMPROVE ANTI-CANCER DRUGS 5 6 
Introduction 
Understanding the mechanistic links between autophagy and apoptosis will aid in 
future therapies aimed at influencing cell fate. There are currently dozens of clinical 
trials using autophagy inhibitors such as chloroquine or hydroxychloroquine, but there is 
little mechanistic insight into how autophagy inhibition kills more cancer cells when 
combined with chemotherapeutic agents or targeted therapies (Levy et al., 2017b; 
Towers and Thorburn, 2016). Here, I expand on the mechanism described in Chapter III 
to explain why autophagy inhibition can increase the effectiveness of anti-cancer drugs, 
such as doxorubicin and etoposide, by causing more apoptosis. Moreover, this 
mechanism also allows autophagy inhibitors to change the mode of action of an MDM2 
inhibitor from growth arrest to apoptosis, even though MDM2 inhibitors alone are often 
known to merely cause growth inhibition and fail to induce tumor cell apoptosis 
(Burgess et al., 2016). Thus, by capitalizing on a mechanism that connects autophagy 
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Autophagy Inhibition Mediates Apoptosis Sensitization in Cancer Therapy by Relieving 
FOXO3a Turnover.  
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https://doi.org/10.1016/j.devcel.2018.02.014  
 
6 Portions of this chapter were published with permission from Oncotarget: 
Autophagy inhibition improves anti-cancer drugs via FOXO3a activation.  




to apoptosis, it is feasible to improve and even change the mode of action of an anti-
cancer drug. 
Results 
I tested if the FOXO3a mediated PUMA activation mechanism described in 
Chapter III is important for sensitizing cells to anti-cancer drugs upon autophagy 
inhibition. Consistent with previous studies using anti-cancer drugs, etoposide (Figure 
4.1a-b) or doxorubicin (Figure 4.1c-d) caused greater caspase 3/7 activity when 
combined with autophagy inhibition by chloroquine compared to the individual agents. 
However, this ability of autophagy inhibition to sensitize parental HCT116 tumor cells to 
drug-induced apoptosis was abolished in isogenic cells that either lack PUMA  
(PUMA-/-) or merely lack the ability to bind FOXO3a at the single site in the PUMA 
locus ( FHRE) (Figures 4.2a-d). These data suggest that the ability of autophagy 
inhibitors like chloroquine to sensitize tumor cells to apoptosis by standard 
chemotherapy is via the FOXO3a-dependent mechanism described above. Moreover, 
although autophagy inhibition can lead to increased transcription of other FOXO3a 
target genes (Figure 3.6a-d), including other pro-apoptotic genes including BIM (Figures 
3.5g and 3.5h), BNIP3 (Figure 3.6c), and BNIP3L (Figure 3.6d) the increased drug-
induced apoptosis observed when autophagy is blocked is mediated largely through a 
single binding site in the PUMA gene.  
I next asked if this idea could be taken a step further and change the mode of 
action of a drug. Nutlin is an inhibitor of MDM2 that activates the p53 transcriptional 
program including PUMA but only results in growth inhibition rather than tumor cell 
death in most cancer cell types  
Figure 4.1
The combination of autophagy inhibition and anti-cancer agents induces more 
cancer cell apoptosis 
(a) HCT116 cells were treated with vehicle, chloroquine 40 µM, etoposide 2.5 µM, or 
etoposide + chloroquine. Caspase-3/7 activation (an indicator of apoptosis execution) 
was measured and normalized to cell number per mm2.
(b) Representative images of caspase-3/7 activation from (a) treated with vehicle, 
chloroquine 40 µM, etoposide 2.5 µM, or etoposide + chloroquine.
(c) HCT116 cells were treated with vehicle, chloroquine 40 µM, doxorubicin 2.5 µM, or 
doxorubicin + chloroquine. Caspase-3/7 activation (an indicator of apoptosis execution) 
was measured and normalized to cell number per mm2. 
(d) Representative images of caspase-3/7 activation from (c) treated with vehicle, 







The combination effect of autophagy inhibition and anti-cancer agents requires 
FOXO3a binding the FHRE to induce apoptosis 
(a) HCT116 parental cells, PUMA-/- cells, or ΔFHRE cells lacking the endogenous 
Forkhead Response Element in the BBC3/PUMA locus, were treated with etoposide 2.5 
µM + chloroquine 40 µM. Caspase-3/7 activation was measured and normalized to cell 
number per mm2.
(b) Representative images of caspase-3/7 activation from (a) in HCT116 parental cells, 
PUMA-/- cells, or ΔFHRE cells lacking the Forkhead Response Element in the 
endogenous BBC3/PUMA locus treated with etoposide 2.5 µM + chloroquine 40 µM.
(c) HCT116 parental cells, PUMA-/- cells, or ΔFHRE cells lacking the endogenous 
Forkhead Response Element in the BBC3/PUMA locus were treated with doxorubicin 
2.5 µM + chloroquine 40 µM. Caspase-3/7 activation was measured and normalized to 
cell number per mm2.
(d) Representative images of caspase-3/7 activation from (c) in HCT116 parental cells, 
PUMA-/- cells, or ΔFHRE cells lacking the Forkhead Response Element in the 
endogenous BBC3/PUMA locus treated with doxorubicin 2.5 µM + chloroquine 40 µM.
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(Huang et al., 2009; Paris et al., 2008; Tovar et al., 2006). I used publicly available 
datasets (Garnett et al., 2012) to identify determinants of Nutlin response and found that 
PUMA levels, but not other BH3-only proteins, is positively correlated with Nutlin 
sensitivity (IC50 < 5μM) in different cell types (Figures 4.3a-d). This led us to hypothesize 
that by combining MDM2 inhibition with autophagy inhibition, both of which increase 
PUMA levels but through different transcription factors (i.e. p53 and FOXO3a, 
respectively), it might be possible to enhance PUMA transcription more than with MDM2 
inhibition alone and thus cause cancer cells that would otherwise only undergo growth 
inhibition with Nutlin to commit to apoptosis instead.  
Consistent with this hypothesis, Nutlin plus bafilomycin A1 or chloroquine caused 
a greater increase in PUMA mRNA levels compared to either compound alone (Figure 
4.4a). Previous reports (Paris et al., 2008; Tovar et al., 2006) indicate that HCT116 cells 
undergo growth arrest upon treatment with Nutlin, but no apoptosis. Consistent with 
this, the combination of Nutlin and chloroquine was much more effective at reducing 
colony formation than either drug alone (Figure 4.4b). As expected, Nutlin alone caused 
a robust cytostatic effect, however, Nutlin plus chloroquine resulted in a reduction in 
tumor cell number (Figure 4.4c) and resulted in more cell death compared to each agent 
alone as measured by a cell permeable dye (Figures 4.4d-e). Only the combination of 
Nutlin and either pharmacological or genetic autophagy inhibition was able to increase 
caspase 3/7 activity (Figures 4.4f-g, and 4.4h-j). Caspase activation was greatly 
reduced in HCT116 cells lacking either PUMA or containing deletions in the single 
FOXO3a-binding FHRE in the PUMA gene locus (Figures 4.4k-m). However, cells that 

































































































PUMA levels, but not other BH3-only proteins, are positively correlated with 
Nutlin sensitivity 
(a) Publicly available gene expression dataset of cancer cell lines from multiple tumor 
types via Oncomine shows that cell lines sensitive to Nutlin (median inhibitory 
concentration <5 µM) have increased expression of BBC3/PUMA. 
(b) Publicly available gene expression data set of cancer cell lines from multiple tumor 
types via Oncomine shows Nutlin resistant (IC50 > 5 μM) or Nutlin sensitive (IC50 < 5 
μM) cell lines and their relative BAD expression levels.
(c) Publicly available gene expression data set of cancer cell lines from multiple tumor 
types via Oncomine shows Nutlin resistant (IC50 > 5 μM) or Nutlin sensitive (IC50 < 5 
μM) cell lines and their relative BIM/BCL2L11 expression levels.
(d) Publicly available gene expression data set of cancer cell lines from multiple tumor 
types via Oncomine shows Nutlin resistant (IC50 > 5 μM) or Nutlin sensitive (IC50 < 5 
μM) cell lines and their relative BID/BCL2L13 expression levels.
Values were Log2 transformed and the median values were scaled to zero according to 
Garnett et al., (2012).
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FOXO3a-mediated upregulation of PUMA changes the mode of action of an anti-
cancer drug 
(a) HCT116 cells were treated with vehicle, bafilomycin A1 10 nM, chloroquine 40 µM, 
Nutlin 20 µM (an MDM2 inhibitor that activates p53), Nutlin + bafilomycin A1, or Nutlin + 
chloroquine) for 24 hr, and the resulting BBC3/PUMA mRNA levels were measured 
relative to 18S rRNA control. 
(b) Clonogenic survival assay using HCT116 cells treated for 72 hr with vehicle, 
chloroquine 40 µM, Nutlin 20 µM, or Nutlin + chloroquine. Cells were then allowed to 
grow back for 7 days in full media.
(c) HCT116 cells were treated with vehicle, chloroquine 40μM, Nutlin-3a 20μM—an 
MDM2 inhibitor that activates p53, or Nutlin-3a + chloroquine for 24 hrs and normalized 
cell count was measured per mm2.
(d) HCT116 cells were treated with vehicle, chloroquine 40 µM, Nutlin 20 µM, or Nutlin + 
chloroquine. Cell permeability by SYTOX green (an indicator of cell death) was 
measured and normalized to cell number per mm2. 
(e) Representative images from (d) of cell permeability by SYTOX green in HCT116 
parental cells treated with vehicle, chloroquine 40 mM, Nutlin 20 mM, or Nutlin + 
chloroquine.
(f) HCT116 cells were treated with vehicle, chloroquine 40 µM, Nutlin 20 µM, or Nutlin + 
chloroquine. Caspase-3/7 activation (an indicator of apoptosis execution) was measured 
and normalized to cell number per mm2.  
(g) Representative images of caspase-3/7 activation from (f) in HCT116 parental cells 
treated with vehicle, chloroquine 40 µM, Nutlin 20 µM, or Nutlin + chloroquine.
(h) HCT116 cells were treated with bafilomycin 10nM, an autophagy inhibitor, Nutlin-3a 
20μM—an MDM2 inhibitor that activates p53, or Nutlin-3a + bafilomycin. Caspase 3/7 
activation (an indicator of apoptosis execution) was measured over the indicated time 
points.
(i) HCT116 cells were transduced with lentiviral shCtrl, shATG5, or shATG7 and the level 
of knockdown is shown for panel j.
(j) HCT116 cells were transduced with lentiviral shCtrl, shATG5, or shATG7 and treated 
with vehicle or Nutlin-3a 20μM for 24hrs. Caspase 3/7 activation was measured and 
normalized to cell number per mm2.
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(k) HCT116 parental cells or ΔFHRE cells lacking the endogenous Forkhead Response 
Element in the BBC3/PUMA locus were treated with Nutlin 20 µM + chloroquine 40 µM. 
Caspase-3/7 activation was measured and normalized to cell number per mm2. 
(l) Representative images of caspase-3/7 activation from (k) in HCT116 parental cells or 
ΔFHRE cells lacking the Forkhead Response Element in the endogenous BBC3/PUMA 
locus treated with Nutlin 20 µM + chloroquine 40 µM.
(m) HCT116 parental or PUMA-/- cells were treated with Nutlin-3a + bafilomycin or 
vehicle for indicated duration. Caspase 3/7 activation (an indicator of apoptosis 
execution) was measured over the indicated time points.
(n) HCT116 parental cells, PUMA-/- cells, or ∆FHRE cells lacking the endogenous 
Forkhead Response Element in the BBC3 locus were treated with staurosporine 200nM. 




cells when treated with the broad apoptotic stimulus, staurosporine (Figure 4.4n). Taken 
together, these data indicate that the mechanism whereby autophagy inhibition 
promotes FOXO3a-driven PUMA expression is necessary for the combination effect of 
Nutlin and autophagy inhibitor that leads to tumor cell apoptosis rather than growth 
arrest.  
A similar combinatorial effect of Nutlin and autophagy inhibition on gene 
activation of BIM, or other BH3 proteins, was not observed (Figure 4.5a). And although 
HCT116 cells had low apoptosis sensitivity upon BIM shRNA knockdown (Figure 4.5b), 
this occurred independent of BIM transcriptional regulation by Nutlin and autophagy 
inhibition. Thus, the primary mechanism by which the drug combination causes the 
switch to apoptosis seems to be mediated through the PUMA gene suggesting that the 
ability to activate two transcription factors (p53 and FOXO3a) that target the same gene 
(i.e. PUMA) is important for mediating apoptosis ability by the p53-activating drug upon 
autophagy inhibition. 
Consistent with the in vitro studies, xenografted tumors grown from HCT116 
parental cells responded to the combination of Nutlin and chloroquine by enhancing 
PUMA mRNA levels better than either drug alone (Figure 4.5c). However, tumors from 
HCT116 cells lacking the endogenous Forkhead Response Element ( FHRE) treated 
with the combination of Nutlin and chloroquine did not show this effect. As expected for 
a compound that activates p53, other p53 target genes, including BAX and p21, were 
also upregulated (Figure 4.5d). Importantly, mice with tumors grown from the parental 
HCT116 cells had markedly improved survival due to tumor burden by the drug 
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FOXO3a-mediated upregulation of PUMA changes the mode of action of an anti-
cancer drug in vivo
79
Figure 4.5
FOXO3a-mediated upregulation of PUMA changes the mode of action of an anti-
cancer drug in vivo
(a) HCT116 cells were treated with vehicle, chloroquine 40μM, Nutlin-3a 20μM—an 
MDM2 inhibitor that activates p53, or Nutlin-3a + chloroquine
for 24 hrs and the resulting BBC3 (PUMA), BIM, BNIP3, and BNIP3L mRNA levels were 
measured relative to 18s rRNA control.
(b) (left) Parental or ∆FHRE HCT116 cells were transduced with lentiviral shCtrl or 
shBIM shRNAs and treated with Nutlin-3a 20μM and chloroquine 40 μM or vehicle for 
indicated duration. Caspase 3/7 activation was measured and normalized to cell number 
per mm2. (right) mRNA
levels of BIM upon lentiviral shCtrl or shBIM.
(c) Athymic nude mice given subcutaneous parental or ΔFHRE HCT116 tumors were 
treated with vehicle, Nutlin, chloroquine, or Nutlin + chloroquine, and PUMA mRNA 
levels in the tumors were measured relative to 18S rRNA control. 
(d) Harvested tumor tissue QPCR analysis of Bax, and p21 mRNA in tumors treated 
with vehicle, chloroquine, Nutlin-3a, or Nutlin-3a + chloroquine normalized to 18S rRNA
control.
(e) Kaplan-Meier survival curves based on tumor burden of athymic nude mice given 
subcutaneous parental or ΔFHRE HCT116 tumors and treated with vehicle, Nutlin, 
chloroquine, or Nutlin + chloroquine over indicated duration.
(f) (left) Normalized tumor volumes of athymic nude mice subcutaneously injected with 
either HCT116 parental or HCT116 ΔFHRE cells and treated with vehicle, chloroquine, 
Nutlin-3a, or Nutlin-3a + chloroquine over indicated duration. Treatment began when 
80% of the tumors
were 100 mm3. (right) Day 21 tumor volume measurement from left panel comparing 
treatment groups.
(g) Normalized mouse body weights of Parental and ∆FHRE HCT116 tumors treated 
with Vehicle, Nutlin, CQ, or Nutlin + CQ normalized to day 1 of drug treatments.
80
 81 
the single FHRE in the PUMA locus displayed no better survival due to tumor burden 
with the combination treatment than was seen with Nutlin alone in the HCT116 parental 
cell tumors (Figure 4.5e). Tumor growth rates were slowest with the drug combination in 
parental HCT116 tumors while tumor growth rate with the drug combination in tumors 
lacking the single FHRE in the PUMA locus were similar to that seen with Nutlin alone in 
the HCT116 parental tumors (Figure 4.5f). In contrast to the improvement in survival 
due to tumor burden (Figure 4.5e), the robust cytostatic effect of Nutlin alone meant that 
the study did not achieve statistical significance (p=0.16) when comparing tumor volume 
of Nutlin treated mice to Nutlin and chloroquine treated mice (Figure 4.5f). Additionally, I 
noted increased toxicity (e.g. as determined by weight loss, Figure 4.5g) in animals 
treated with the drug combination that led some animals to be removed from the study 
irrespective of their tumor burden. This is consistent with recent clinical studies where it 
has been found that autophagy inhibition with chloroquine or hydroxychloroquine can 
increase the toxicities that are known to be caused by the other drug that is used in 
combination (Levy et al., 2017a). 
Discussion 
There are many ongoing clinical trials to inhibit autophagy for cancer therapy 
(Levy et al., 2017a; Towers and Thorburn, 2016). The underlying idea is to enhance 
tumor cell apoptosis and thus make other drugs work more effectively but the molecular 
mechanism by which this occurs has been unclear, making it difficult to determine which 
drugs might benefit from autophagy inhibition. The regulatory mechanism identified in 
Chapter III begins to solve these problems and my data indicate that the ability of an 
autophagy inhibitor to increase tumor cell apoptosis by standard chemotherapy drugs 
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like etoposide or doxorubicin requires that FOXO3a be able to increase PUMA gene 
expression. Moreover, I also show that it is possible to exploit the mechanistic link 
between autophagy homeostasis and apoptosis sensitivity to improve the therapeutic 
efficacy of an anti-cancer drug like Nutlin that often only causes growth inhibition of 
cancer cells (Huang et al., 2009; Paris et al., 2008; Tovar et al., 2006) into one that kills 
cancer cells. Thus, pharmacological manipulation of the autophagic turnover of a 
transcription factor can work through a single genomic binding site in one gene to 
improve the ability of cancer drugs to cause tumor cell apoptosis and can even change 
the mode of action of a highly specific anti-cancer drug. Since there are several MDM2 
inhibitors in clinical development (Burgess et al., 2016), my work suggests that they 
could be good candidates for combination with autophagy inhibition in the clinic 
(Sullivan et al., 2015). However, the increased general toxicity that I observed with the 
drug combination means that as with other attempts to widen the therapeutic window for 
a given cancer drug by inhibiting autophagy, it will be important to optimize doses of 
both the MDM2 inhibitor and the autophagy inhibitor in clinical studies.  
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FOXO3A DEGRADATION BY AUTOPHAGY, BUT NOT THE PROTEASOME, 
CONFERS APOPTOSIS SENSITIZATION 
Introduction 
In Chapters III and IV, I discovered one of the first reports of a transcription factor 
being selectively targeted for autophagic degradation, and ascribe a physiological role 
for this regulation—namely, dictating apoptosis threshold in cancer cells. FOXO3a is 
also regulated by the proteasome in response to various stimuli. I wondered if this 
proteasomal regulation also influences the likelihood of a cell undergoing apoptosis in 
response to anti-cancer therapies. Previous studies show that growth factor stimulation 
results in increased ERK and Akt signaling, leading to FOXO phosphorylation and 
sequestration in the cytoplasm where the E3 ubiquitin ligase SKP2 induces 
ubiquitination and subsequent degradation by the proteasome (Huang and Tindall, 
2011). Similarly, ERK activation via the Ras-Raf-MEK pathway leads to FOXO3a 
phosphorylation and recognition by the E3 ubiquitin ligase MDM2, leading to 
proteasomal degradation (Huang and Tindall, 2011; Yang et al., 2008). These studies 
point to FOXO regulation in response to physiological signaling, and prompted me to 
test the contribution of proteasomal degradation to FOXO3a stability in cancer cells.  
Results 
 I began by testing the relative contributions of both the proteasome and 
lysosome to FOXO3a degradation. Bortezomib, a proteasome inhibitor, bafilomycin A1, 
a lysosome inhibitor, and the combination caused a time-dependent accumulation of the 
FOXO3a protein in HCT116 cells that peaked at 8 hours following treatment (Figure 
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5.1a). Bortezomib is known to active the p53 transcriptional program by preventing the 
proteasomal degradation of p53 (Williams and McConkey, 2003), so the protein levels 
of the p53 protein are displayed as a positive control. These data indicate that both the 
proteasome and autophagy pathways contribute to regulating FOXO3a protein levels. 
Next, I tested the effect of these increases in FOXO3a levels on PUMA mRNA levels in 
HCT116 cells. Consistent with data presented in Chapter III, bafilomycin A1 treatment 
led to an increase in PUMA mRNA levels at both 8 and 24 hours (Figure 5.1b). 
Bortezomib treatment also caused an increase in PUMA mRNA levels (Figure 5.1b), but 
this increase was dependent on p53—performing these experiment in p53-/- HCT116 
cells abolished the effects of bortezomib without affecting bafilomycin A1’s ability to 
increase PUMA mRNA (Figure 5.1c). These data show that despite both proteasome 
and lysosomal turnover, FOXO3a only increases PUMA mRNA levels when treated with 
bafilomycin A1. 
 In Chapter IV, I demonstrated that HCT116 cells undergo growth arrest when 
treated with Nutlin, but commit to apoptosis if they are treated with a lysosome inhibitor 
like chloroquine. Also, I showed that this combinatorial effect was dependent on the 
ability of FOXO3a to bind to the PUMA gene at the FHRE—deletion of this binding site 
reversed these effects. Next, I compared the amount of caspase 3/7 activity in both 
parental and ∆FHRE HCT116 cells treated with Nutlin and bortezomib, and found that 
there was no difference in apoptosis between these cell lines (Figure 5.2a). Though the 
combination of Nutlin and bortezomib caused apoptosis, this effect was not dependent 






































































































FOXO3a levels increase upon autophagy and proteasome inhibition, but 
transactivate PUMA via different transcription factors
(a) Western blot analysis of HCT116 cells treated with vehicle, bafilomycin A1 10nM, 
bortezomib 50nM, or the combination for indicated duration
(b) HCT116 cells were treated with vehicle, bafilomycin A1 10 nM, bortezomib 50nM for 
8 hr or 24 hr and the resulting BBC3/PUMA mRNA levels were measured relative to 18S 
rRNA control. 
(c) HCT116 p53-/- cells were treated with vehicle, bafilomycin A1 10 nM, bortezomib
50nM for 8 hr or 24 hr and the resulting BBC3/PUMA mRNA levels were measured 




Autophagy-directed, but not proteasome, FOXO3a turnover confers apoptosis 
sensitization
(a) Parental or ΔFHRE HCT116 cells were treated with vehicle, bortezomib 50nM, Nutlin
20 µM, or Nutlin + bortezomib. Caspase-3/7 activation (an indicator of apoptosis 
execution) was measured and normalized to cell number per mm2.
(b) Confocal images of HCT116 cells expressing mCherry-GFP-FOXO3a treated with 
bafilomycin A1 10nM or bortezomib 50nM for 8 hr.
Scale bars, 10 µm. 
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cells with bortezomib did not cause nuclear translocation of FOXO3a, but as expected 
bafilomycin A1 was capable of promoting nuclear enrichment of FOXO3a (Figure 5.2b). 
Taken together, FOXO3a is degraded by both the lysosomal and proteasome, but only 
lysosomal blockage was able to cause FOXO3a activation and subsequent increases in 
PUMA levels. 
Discussion 
The data in Chapter V create a very interesting set of findings; although both the 
proteasome and autophagy are responsible for turnover of FOXO3a, only the protein 
that is degraded by autophagy is able to activate PUMA transcription when its turnover 
is blocked. This may represent an example whereby the same protein is degraded by 
two distinct mechanisms but only one of the mechanisms is linked to another process 
(in this case apoptosis sensitization). Although I do not understand the molecular 
mechanism yet, this suggests that there may be different pools of FOXO3a that are 
degraded by the proteasome and the autophagosome and only blocking the one 
process leads directly to increased transcription of FOXO targets. Future studies should 
aim to understand the specific post-translational modifications that direct different 
FOXO3a protein pools to their respective regulation pathways. One approach for 
experimental testing may include mass spectrometry studies in vehicle, bafilomycin A1 
(a lysosomal inhibitor), and bortezomib (a proteasome inhibitor) treated cells to 
determine the modifications of FOXO3a specific to each inhibitor. Once a critical 
modification necessary for autophagic targeting is determined, additional experiments 
should involve expressing a mutant version of that protein to show an inability to be 
recruited to autophagosomes. These experiments could reveal how the cell directs a 
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protein pool toward a specific function, and how differential modifications can influence 
cellular fate. This underscores the importance of knowing the specific molecular 





















DEVELOPMENT OF AN OPTOGENETIC METHOD TO RAPIDLY BLOCK 
AUTOPHAGY 
Introduction 
Current methods of autophagy inhibition include pharmacological or genetic 
manipulation by shRNA knockdown or CRISPR/Cas9-mediated knockout of essential 
autophagy regulators, but takes ~48hrs to achieve a substantial level of autophagy 
inhibition (Staskiewicz et al., 2013). Pharmacological autophagy inhibition can be 
achieved more quickly, with bafilomycin A1 working more rapidly than chloroquine, at 
blocking autophagosome-lysosome fusion (Collins et al., 2018; Mauthe et al., 2018), but 
both lack pathway specificity and promote off-target effects. If, for example, we were 
interested in testing the immediate effects of autophagy blockade on a particular 
signaling cascade, using these sluggish and non-specific methods would not allow for 
dissecting this biology.  
In this Chapter, I will describe the development of an optogenetic system to 
achieve rapid and specific autophagy inhibition within a manner of minutes. I show that I 
can use light to block autophagy and cause accumulation of autophagy substrates, with 
no background activity in the dark. Further, I show that I can kill cancer cells with light 
that are dependent on autophagy for survival. Consistent with data shown in Chapter IV, 
I also demonstrate that I can change the mode of action of the anti-cancer drug Nutlin 
from growth arrest to apoptosis using autophagy inhibition with light. Using a pH-
sensitive fluorophore tagged to an autophagy cargo protein, I provide preliminary data 
showing that this optogenetic system can block the delivery of new cargo to the 
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lysosome within a matter of minutes. I termed this optogenetic autophagy inhibition 
system Autophagic SNARE for Abrupt Photoinhibition (ASAP). 
Results 
Syntaxin 17 (STX17) is a SNARE protein that has been previously shown to be 
important for autophagosome-lysosome fusion to occur, and expressing a mutant 
lacking the N-terminus of the protein (STX17∆NTD) acts as a dominant negative to 
inhibit fusion (Itakura et al., 2012; Uematsu et al., 2017). STX17 has been shown to 
localize to the mitochondrial surface (Arasaki et al., 2015), so I decided to target 
STX17∆NTD to mitochondria using a TOM20 targeting sequence. In order to create a 
rapid optogenetic system whereby autophagy is functional in the dark but inhibited with 
incidence of light, I chose to use a photocleavable protein called PhoCL (Zhang et al., 
2017). When cells expressing this plasmid (pBABE TOM20-PhoCL-myc-STX17∆NTD) 
are kept in the dark, the STX17∆NTD fragment remains tethered to mitochondria by 
PhoCL and is not able to inhibit autophagosome-lysosome fusion (Figure 6.1a). 
Conversely, upon 405nm light incidence, PhoCL is cleaved and the STX17∆NTD 
fragment is released to inhibit autophagosome-lysosome fusion by acting as a dominant 
negative (Figure 6.1a). When PhoCL is full-length it is fluorescent and excited by 
488nm, but upon 405nm light incidence, is cleaved and loses its fluorescence (Figure 
6.1a). Upon expressing this system in MCF10a cells, as expected the ASAP system 
localizes to mitochondria (Figure 6.1b). In the dark, the ASAP system is fluorescent and 
localized to mitochondria, but upon 405nm stimulation is transiently photo-converted to 
a species that is excited by ~570nm (Zhang et al., 2017), and then becomes cleaved 
(Figure 6.1c).  
a. b.
Figure 6.1
Autophagy SNARE for Abrupt Photoinhibition (ASAP) system
(a) Schematic representation of how the ASAP optogenetic system works to block 
autophagy with 405nm light treatment, but maintains functional autophagy in the dark. 
(b) Confocal images of MCF10a cell expressing TOM20-PhoCL-myc-STX17ΔNTD 
(ASAP) and treated with MitoTracker mitochondrial stain. Scale bars=10µm.
(c) Confocal images of MCF10a cell expressing TOM20-PhoCL-myc-STX17ΔNTD 





To test if the ASAP system inhibits autophagy with 405nm light stimulation but 
not affecting autophagy in the dark, I monitored autophagy substrates by western blot 
analysis. BT549 cells expressing ASAP in the dark show an expected increase in the 
autophagy cargo receptor p62/SQSTM1 with the lysosome inhibitor bafilomycin A1, and 
a comparable increase in p62/SQSTM1 with 405nm light treatment. Further, the 
combination of autophagy inhibition by bafilomycin A1 and 405nm light did not cause a 
further increase in p62/SQSTM1 (Figure 6.2a). Autophagy inhibition with the ASAP 
system also caused in increase in other autophagy substrates FOXO3a and LC3-II in 
multiple cell lines that did not increase further with bafilomycin A1 treatment (Figure 
6.2b-c). Taken together, these data indicate that the ASAP optogenetic system can 
inhibit autophagy following 405nm light stimulation causing established autophagy 
substrates to accumulate. Next, because the cleavage product resulting from 405nm 
light stimulation causes autophagy inhibition, I was interested in the stability of this 
cleaved fragment. I treated ASAP cells with 405nm light (or kept in the dark) and 
harvested 1 hour, 8 hours, and 12 hours after, then detected the amount of ASAP 
cleavage fragment and its effects on autophagy substrates FOXO3a and LC3-II 
(Figures 6.2d-e). Of note, cells expressing ASAP in the dark showed no photocleavage, 
suggesting that there is minimal background inhibition of autophagy.  
Some cancer cells are more dependent on autophagy for survival than others 
(Maycotte et al., 2014). BT549 cells have been previously shown to be sensitive to 
autophagy inhibition; treatment with the lysosomal inhibitor chloroquine or bafilomycin 
A1 causes a decrease in growth (Figure 6.3a). Expression of the ASAP optogenetic 




Autophagy SNARE for Abrupt Photoinhibition (ASAP) system allows for light-
mediated autophagy inhibition in multiple cancer cell lines.
(a) Western blot analysis of BT549 cells treated with 405nm light or kept in the dark in 
the absence or presence of bafilomycin A1 10nM. 
(b) Western blot analysis of BT549 cells treated with 405nm light or kept in the dark in 
the absence or presence of bafilomycin A1 10nM. 
(c) Western blot analysis of MCF10a cells treated with 405nm light or kept in the dark in 
the absence or presence of bafilomycin A1 10nM. 
(d) Western blot analysis of BT549 cells treated with 405nm light and harvested at 
indicated duration after 405nm light treatment. 
(e) Western blot analysis of HCT116 cells treated with 405nm light and harvested at 





Autophagy inhibition kills autophagy-dependent cancer cells 
(a) BT549 Parent cells were treated with vehicle, bafilomycin A1 10nM, or chloroquine 
40µM for indicated duration and cell confluence was normalized to time point 0. 
(b) BT549 Parent or ASAP (in the dark) cells were treated with vehicle, bafilomycin A1 




that the ASAP system has no background effects on autophagy or cell growth in the 
dark (Figure 6.3b). Next, I tested the hypothesis that the ASAP system could alter the 
growth of BT549 cells following 405nm light incidence compared to cells kept in the 
dark. Indeed, ASAP cells treated with 405nm light displayed less growth compared to 
ASAP cells kept in the dark (Figure 6.4a). ASAP cells treated with light causes a more 
rapid effect on cell growth than ASAP cells (in the dark) treated with the autophagy 
inhibitor bafilomycin A1 (Figure 6.4a). The ability of ASAP to affect cell growth upon 
treated with 405nm light is dose-dependent (Figure 6.4b), and is able to cause 
apoptosis, compared to parental cells treated with the same light dosage (Figure 6.4c). 
Because the ability of ASAP to inhibit autophagy is dependent on the amount of the 
photocleaved fragment, and previous results show the half-life of this fragment to be ~6 
hours, this ASAP system has a transient effect on cell growth compared to chloroquine 
(Figure 6.4d). Taken together, these data show the ability of the ASAP system to rapidly 
and transiently inhibit autophagy, and to subsequently elicit biological effects on tumor 
cell survival in a cell line that is known to undergo apoptosis upon autophagy inhibition 
by other methods with no background activity in the dark.  
Previous reports from the Thorburn laboratory have shown that inhibiting 
autophagy can sensitize cells to apoptosis (Fitzwalter et al., 2018; Thorburn et al., 
2014). Treating some cancer cells with the anti-cancer drug Nutlin alone causes growth 
arrest, but when combined with an autophagy inhibitor can promote commitment to 
apoptosis. This demonstrates that autophagy inhibition can change the mode of action 
of a cancer therapy from growth arrest to cell death, like I showed in Chapter IV 




Autophagy SNARE for Abrupt Photoinhibition (ASAP) system can kill autophagy-
dependent cancer cells in a rapid and transient manner. 
(a) BT549 ASAP cells were treated with vehicle, bafilomycin A1 10nM, or 405nm light for 
indicated duration and cell confluence was normalized to time point 0. 
(b) BT549 Parent or ASAP cells were treated with two doses of 405nm light for indicated 
duration and cell confluence was normalized to time point 0. 
(c) BT549 Parent or ASAP cells were treated with 405nm light for indicated duration and 
caspase 3/7 activity was measured per mm2 and normalized to time point 0. 
(d) BT549 ASAP cells were treated with vehicle, chloroquine 40µM, or 405nm light for 
indicated duration and cell confluence was normalized to time point 0. 
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effects of ASAP on mitochondrial biology, I made ASAP control cells that have a 
mitochondrial-targeted PhoCL that undergoes light-induced cleavage, but lacks the 
STX17∆NTD, and thereby does not inhibit autophagy with light (Figure 6.5a). I show 
that ASAP cells (in the dark) treated with the combination of Nutlin and the autophagy 
inhibitor chloroquine leads to a decrease in cell confluence (Figure 6.5b) and an 
increase in caspase 3/7, a marker of apoptosis (Figure 6.5c), compared to each drug 
alone. Importantly, the treatment of ASAP control or ASAP cells with 405nm light and 
Nutlin led to an abrupt decrease in cell confluence in the ASAP cells (Figure 6.5d) and 
an increase in apoptosis compared to ASAP control cells with the same treatment 
(Figure 6.5e). These data provide a rigorous test of the ability of the optogenetic method 
to inhibit autophagy in a rapid manner and cause a biological effect. 
To determine how rapidly ASAP can block autophagy, I chose to develop a way 
to detect the delivery of autophagy substrates to the lysosome in real time. I achieved 
this using a pH-sensitive fluorophore called pHRed that has minimal fluorescence under 
physiological pH (pH~7), but strongly fluoresces in acidic compartments, such as 
lysososomes (pH~4) (Tantama et al., 2011). I tagged this fluorophore to the autophagy 
cargo receptor protein p62 to watch the kinetic delivery of p62 to lysosomes (Figure 
6.6a). I observed robust colocalization of pHRed-p62 with lysotracker, indicating that 
this tool can detect delivery of p62 to lysosomal compartments (Figure 6.6b). To detect 
the dynamic delivery of new pHRed-p62 molecules to lysosomes, I performed localized 
photobleaching on a region of interest (ROI) and monitored the subsequent recovery of 
fluorescence after photobleaching (FRAP) of that ROI. Because photobleaching causes 









Autophagy SNARE for Abrupt Photoinhibition (ASAP) system can kill autophagy-
dependent cancer cells.
(a) Schematic representation of the ASAP control and ASAP protein products used for 
experimentation.
(b) HCT116 ASAP control cells were treated with vehicle, Nutlin 20µM, chloroquine 
40µM, or Nutlin + chloroquine for indicated duration. Percent confluence was measured 
and normalized to time point 0. 
(c) HCT116 ASAP control cells were treated with vehicle, Nutlin 20µM, chloroquine 
40µM, or Nutlin + chloroquine for indicated duration. Caspase-3/7 activation was 
measured and normalized to cell number per mm2.
(d) HCT116 ASAP cells were treated with vehicle or Nutlin 20µM and 405nm light. 
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pHRed-p62 reveals rapid, successive substrate delivery to lysosomes
(a) Schematic representation of how pHRed-p62 works to monitor the delivery of p62 to 
lysosomes. pHRed-p62 is fluorescent in cellular compartments with low pH, such as 
lysosomes, but is not fluorescent in pH-neutral environments. 
(b) Representative confocal images of MEFs starved for 4hrs in EBSS expressing 
pHRed-p62 (red) and treated with lysotracker (green).
(c) Confocal image series of MEF starved for 4hrs in EBSS expressing pHRed-62 and 
photobleached at 561nm for 1ms at 50% laser power. Time is indicated in minutes. 
(d) Quantitation of mean fluorescent intensity of ROI indicated following photobleaching
of pHRed-p62 at 561nm for 1ms at 50% laser power.
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newly delivered pHRed-p62 molecules to lysosomes. p62-/- mouse embryonic 
fibroblasts (MEFs) were starved for 4 hours using EBSS, and subject to photobleaching 
in an ROI (Figure 6.6c). The fluorescent recovery over time of this ROI was then 
quantified (Figure 6.6d). These experiments reveal that under starvation conditions 
there is rapid, successive delivery of pHRed-p62 to lysosomes (Figure 6.6c-d). Next, I 
tested the hypothesis that the rapid delivery of pHRed-p62 in these experiments is due 
to autophagosome-lysosome fusion events. To visualize such events, I expressed a 
previously described (Itakura et al., 2012) marker of autophagosomes, GFP-STX17TM, 
along with pHRed-p62 and discovered that lysosomes can accommodate multiple 
autophagosome fusion events (Figure 6.7a). 
In Figures 6.2-6.5, I validated the ability of ASAP to inhibit autophagy by 
functional and biochemical assays; however, these techniques are not able to 
determine how rapidly ASAP can block autophagosome-lysosome fusion. To measure 
this timescale, I combined the ASAP optogenetic system with pHRed-p62 to uncover 
how quickly ASAP can block the new delivery of pHRed-p62 to lysosomes. p62-/- MEFs 
were starved using EBSS, subject to photobleaching at two ROIs, and the fluorescent 
recovery of these ROIs was monitored over time (Figure 6.8a). Next, using the same 
cell, I photoactivated ASAP using 405nm light to inhibit autophagosome-lysosome 
fusion and then photobleached three ROIs (Figure 6.8b). Of note, and consistent with 
previous studies, there is a transient burst of red fluorescence of PhoCL just prior to 
photocleavage (Zhang et al., 2017). Quantitation of these photobleached ROIs both 
before and after ASAP activation revealed that ASAP could block the delivery of new 
pHRed-p62 to lysosomes (Figure 6.8c). Although these experiments have not been  
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Lysosomes can accommodate multiple autophagosome fusion events
(a) Image series (in minutes) showing a single fusion event in U2OS cells expressing 
Syntaxin 17 Transmembrane domain to mark autophagosomal structures, and pHRed-
p62. Cells were starved using EBSS.
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ASAP blocks autophagic delivery of p62 to lysosomes
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Figure 6.8
ASAP blocks autophagic delivery of p62 to lysosomes
(a) Confocal image series of EBSS-starved MEFs expressing pHRed-62 and ASAP (in 
the dark) and photobleached in ROIs at 561nm for 1ms at 50% laser power. Time is 
indicated in minutes. 
(b) Confocal image series of EBSS-starved MEFs expressing pHRed-62 and ASAP
(stimulated with 405nm laser line) and subsequently photobleached at indicated ROIs at 
561nm for 1ms at 50% laser power. Time is indicated in minutes. 
(c) Quantitation of mean fluorescent intensity of indicated ROIs following photobleaching
in pHRed-p62-expessing and ASAP cells (in the dark or stimulated with 405nm laser 




extensively repeated, these data provide preliminary evidence that ASAP can block the 
delivery of new pHRed-p62 molecules to lysosomes with 405nm light incidence within a 
short timescale. A lot more optimizing of this workflow usiung ASAP and pHRed-p62 is 
needed. To date, I am not aware of any other system to genetically block autophagy 
within a matter of minutes.  
Discussion 
 In this Chapter, I show that I can combine a useful optogenetic protein PhoCL 
with a mutant SNARE protein STX17∆NTD to block the process of autophagy in a light-
dependent manner, with negligible background in the dark. The advent of ASAP will 
allow us the understand the biological effects of blocking autophagy transiently and 
acutely using genetic means, rather than using current methods—pharmacological 
inhibitors that have off-target effects (bafilomycin A1 and chloroquine), and genetic 
manipulations that take a long time to work (shRNA and CRISPR/Cas9).  
I show biochemically that ASAP can inhibit autophagy in a population of cells 
subject to 405nm light exposure, resulting in increased autophagy substrates. 
Additionally, I show proof-of-principle experiments that inhibiting autophagy with the 
ASAP system can kill cancer cells that are dependent on autophagy for survival and this 
death occurs more rapidly than pharmacological inhibitors like chloroquine, which take 
time to accumulate in the lysosome (Collins et al., 2018). ASAP is also able to change 
the mode of action of the anti-cancer drug Nutlin from growth arrest to apoptosis, 
confirming my previous reports (Fitzwalter et al., 2018).  
 To further validate the ASAP system, I sought to determine if I could achieve 
rapid and robust autophagy inhibition within a timescale of minutes. Current methods 
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are incapable of determining if autophagy is inhibited on this short of a timescale, so I 
decided to develop a technique to monitor the real-time delivery of the autophagy 
substrate p62/SQSTM1 to the lysosome. By tagging p62/SQSTM1 to the pH-sensitive 
fluorophore, pHRed, I could observe the population of p62/SQSTM1 that resides in the 
lysosome. Next, to visualize dynamic population of p62/SQSTM1 that was newly-
delivered to the lysosome, I chose to photobleach a select region of the cell to watch the 
rate of recovery of pHRed-p62. I believe that the fluorescent recovery after 
photobleaching (FRAP) is indicative of pHRed-p62 molecules that are newly delivered 
to the lysosome. I am able to visualize autophagy flux in live cells in real time using this 
tool, and are able to test the hypothesis that the ASAP system is blocking autophagy on 
a rapid timescale. Below, I will discuss how future studies could harness the power of 
using light to block autophagy with the ASAP system. 
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DISCUSSION 7 8 
FOXO3a links autophagy to apoptosis 
The work in this Thesis builds on a previous report from the Thorburn laboratory 
showing that autophagy controls the timing and extent of apoptosis by regulating PUMA 
levels (Thorburn et al., 2014). This study demonstrated that autophagy inhibition led to 
increased PUMA protein levels, but the mechanism by which this occurs was not 
resolved. I describe in Chapter III that upon genetic or pharmacological autophagy 
inhibition, the mRNA levels of PUMA increase via new transcription, independent of its 
common transcriptional regulator p53 (Figures 3.1-3.3). This transcriptional activation of 
PUMA was dependent on the Forkhead Box transcription factor FOXO3a binding at a 
single Forkhead Response Element (FHRE) in an intron of the PUMA gene (Figures 
3.4-3.5). Importantly, CRISPR/Cas9-mediated knockout of this endogenous FHRE 
completely blocked the ability of autophagy inhibition to upregulate PUMA mRNA levels, 
but still allowed for PUMA upregulation in other contexts (p53 activation for example) 
(Figures 3.4-3.5).  
                                                 
 
7 Portions of this chapter were published with permission from Oncotarget: 
Autophagy inhibition improves anti-cancer drugs via FOXO3a activation.  
Brent E. Fitzwalter & Andrew Thorburn, 2018, Oncotarget, Vol. 9, (No. 39), pp: 25384-
25385. 
 
8 Portions of this chapter were published with permission from Nature Cell Biology: 
A caspase-independent way to kill cancer cells. 
Brent E. Fitzwalter & Andrew Thorburn, 2017, Nat. Cell. Biol. 2017 Aug 31;19(9):1014-
1015. doi: 10.1038/ncb3604. 
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FOXO transcription factors are known to be regulated by post-translational 
modifications governing their localization and protein stability (Calnan and Brunet, 
2008). In this Thesis, I uncovered a previously undescribed mechanism of FOXO 
regulation—constitutive basal autophagic degradation. FOXO3a is selectively degraded 
by basal autophagy, but this turnover is relieved upon autophagy inhibition, allowing for 
transactivation of PUMA and other gene targets (Figures 3.5-3.9).  
I have discussed how autophagy and cell death are two evolutionarily conserved 
cellular processes that are intimately linked by their molecular machinery (Fitzwalter and 
Thorburn, 2015b). In this Thesis, I believe that I have uncovered a fundamental 
transcriptional mechanism showing how autophagy influences apoptosis. When 
autophagy is intact PUMA levels are kept low, but when autophagy is blocked, PUMA 
mRNA levels are increased by the transcription factor FOXO3a binding to the FHRE in 
the PUMA gene, leading to new transcription. Surprisingly, the FOXO3a protein is 
directly targeted for basal autophagic turnover under normal physiological conditions, 
but upon autophagy inhibition causes FOXO3a to become relieved from this regulation 
allowing for transactivation of numerous gene targets, but most importantly PUMA. This 
mechanism implies that there is a homeostatic feedback loop in place whereby a 
transcription factor that was previously shown to control autophagy (Warr et al., 2013a) 
is itself regulated by autophagic turnover (Fitzwalter and Thorburn, 2018). Further, the 
data from this Thesis also suggests that FOXO3a acts as a cell surveillance sensor to 
maintain autophagy homeostasis; in the case where autophagy is intact, FOXO3a is 
sequestered and degraded in the cytoplasm, but upon autophagy perturbation FOXO3a 
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is relieved from degradation and translocates to the nucleus to correct the distress or 
mediate apoptosis commitment (Figure 7.1).  
There are unanswered questions from this work. My studies showed that the 
transcriptional kinetics of various apoptotic and non-apoptotic FOXO3a targets differ 
following pharmacological and genetic autophagy perturbation (Figure 3.5-3.6); how is 
FOXO3a selectively directed toward a specific set of gene targets, at what kinetics, and 
how do these targets influence cell fate? Above, we discussed the need for mass 
spectrometry experiments to understand the landscape of FOXO3a post-translational 
modifications that may direct FOXO3a to favor the activation of individual targets. 
Understanding FOXO3a post-translational modifications may also help us understand 
how FOXO3a is selectively recruited to phagophores, and what signals allow it to avoid 
autophagic turnover and become activated upon autophagy inhibition. Additionally, data 
from Chapter V show that FOXO3a is degraded by both the proteasome and 
autophagy; however, inhibiting autophagy but not the proteasome causes an increase in 
PUMA mRNA (Figure 5.1) suggesting that there may be different pools of FOXO3a 
destine for different modes of degradation and cellular signaling, which may also be 
explained by different post-translational modifications. Understanding the underlying 
biology of FOXO3a signaling may uncover the molecular consequences of blocking 
autophagy. In the next section, I will discuss how the mechanisms described above can 
be leveraged to improve anti-cancer drugs.  
Autophagy inhibition improves anti-cancer drugs via FOXO3a 
Chapter IV of this Thesis shows that I can take advantage of the molecular 

















FOXO3a may act as a cell surveillance mechanism to maintain autophagy 
homeostasis.
(left) Basal autophagy flux is upheld and homeostasis is maintained. FOXO3 is targeted 
for degradation by basal autophagy to confer low apoptosis sensitivity. (right) FOXO3 
avoids autophagic turnover upon autophagy inhibition (genetic deletion of essential 
autophagy genes or pharmacological inhibition). FOXO3 transactivates autophagy-
related genes and attempts to compensate for the perturbation in autophagy flux; if this 




anti-cancer drugs work better. I show that this molecular mechanism—autophagy’s 
ability to control PUMA levels via FOXO3a—explains why cancer cells are sensitized to 
undergo apoptosis upon autophagy inhibition (Figure 7.2). How can this mechanism 
allow us to improve cancer therapy? I showed that lysosomal disruption by chloroquine 
(a drug that is used in people to inhibit autophagy, but also affect other lysosomal-
related processes and has lysosome independent effects as well) sensitizes cells to 
apoptosis upon treatment with the DNA damaging agents such as doxorubicin and 
etoposide, but this combinatorial effect was dependent on the ability of FOXO3a to bind 
to the PUMA locus at the FHRE (Figures 4.1-4.2). I took the mechanism a step further 
to change the mode of action of an anti-cancer drug called Nutlin from cancer cell 
growth arrest to causing apoptosis commitment upon autophagy inhibition (Figure 4.4). 
These in vitro data indicate that Nutlin and lysosomal inhibition cooperate to cause 
cancer cells to commit to apoptosis, but this cooperation is dependent on the ability of 
FOXO3a to bind to the PUMA locus (Figure 7.3). Similar results were obtained for 
genetic autophagy inhibition and Nutlin combination, indicating that these effects involve 
macroautophagy’s ability to regulate apoptosis and not autophagy-independent effects 
of chloroquine (Figure 4.4). Consistent with these data, mice with xenograft tumors 
grown from parental HCT116 cells and treated with the combination of Nutlin and 
chloroquine had significantly better survival based on tumor burden compared to the 
two drugs alone (Figure 4.5). However, mice with tumors grown from cells lacking the 
endogenous FHRE in the PUMA locus failed to respond to this combination treatment 
and displayed no better survival than parental tumors treated with Nutlin alone (Figure 
4.5). These data indicate that the combination of chloroquine and Nutlin can reduce  
Figure 7.2
Autophagy determines sensitivity to chemotherapy. 
Autophagic turnover of FOXO3a confers low sensitization to chemotherapy-induced 
apoptosis. However, upon autopagy inhibition, FOXO3a transactivation of PUMA 
confers high sensitization to chemotherapy-induced apoptosis. 
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Figure 7.3
Autophagy inhibition mediates apoptosis sensitization in cancer therapy by 
relieving FOXO3a turnover
Schematic of the proposed mechanistic link between autophagy and apoptosis, 
explaining how autophagy inhibitors can improve anti-cancer drugs by increasing 
sensitivity to apoptosis. The transcription factor FOXO3a, an autophagy regulator, is 
itself degraded by basal autophagy. Disruption of autophagy allows FOXO3a to 
upregulate BBC3/PUMA expression and thus cause apoptosis sensitization. 
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tumor burden in vivo, and that this combinatorial benefit of autophagy inhibition depends 
on the ability of FOXO3a to bind to the PUMA locus in these cancer cells. 
MDM2-target therapies, like Nutlin, are currently being tested in patients with 
both solid and non-solid tumors in combination with other anti-cancer therapies 
(Burgess et al., 2016; Tisato et al., 2017). MDM2 inhibitors act as regulators of p53, a 
regulator of cell cycle, cell proliferation, and apoptosis. The mechanism I discovered 
that links autophagy and apoptosis paves the way for future studies aimed at improving 
the therapeutic efficacy of a cancer drug, such as Nutlin. My studies in vitro and in vivo 
suggest that autophagy inhibition can change the mode of action of Nutlin from growth 
arrest to apoptosis in cancer cells. Further, my data suggests that using autophagy 
inhibitors in combination with MDM2 inhibitors may be therapeutically beneficial. It is 
worth noting that I observed increased toxicity in mice treated with the combination of 
Nutlin and chloroquine (Figure 4.5). This toxicity is consistent with previous studies 
aiming to inhibit autophagy in combination with anti-cancer drugs (Levy et al., 2017b). 
One explanation for this toxicity may be that inhibiting autophagy has altered the 
apoptotic threshold in non-cancerous tissues. Future studies could focus on dose 
management in order to reduce toxicity to improve patient outcomes, and determine the 
effect of autophagy inhibition on the therapeutic window of anti-cancer drugs. Future 
studies should also determine if this mechanism applies in a range of cancer types, and 
in the context of other anti-cancer drugs. Additionally, are different cancer sub-types 
dependent on other BH3-only proteins for apoptosis sensitization upon autophagy 
inhibition?  
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Autophagy is believed to prevent tumor initiation by promoting DNA stability, 
mitochondrial turnover, and tissue homeostasis. However, once a tumor has been 
established, autophagy allows cancer cells to overcome nutrient and environmental 
stresses associated with tumor cell proliferation and microenvironment (Galluzzi et al., 
2015). Inhibiting autophagy in cancer may be a therapeutic intervention to promote cell 
death (Levy et al., 2017b; Towers and Thorburn, 2016), and thus understanding the 
molecular mechanisms linking autophagy and apoptosis is essential (Fitzwalter and 
Thorburn, 2015b). Indeed, there are many ongoing clinical trials (Towers and Thorburn, 
2016) using autophagy inhibitors to enhance the efficacy of anti-cancer drugs, but there 
is limited mechanistic insight as to why they cooperate to induce more tumor cell death. 
The work described in Chapters III and IV begins to provide a mechanistic rationale for 
combining anti-cancer drugs and autophagy inhibitors. Namely, blocking autophagy 
leads to apoptosis sensitivity by relieving FOXO3a from autophagic turnover, allowing 
for the active transcription and increase in PUMA levels. My work suggests that cancer 
cells may use autophagy to keep FOXO3a levels (and thereby PUMA levels) low to 
resist apoptosis. Hundreds of published studies show that if autophagy is inhibited in 
cancer cells by inhibition of specific ATG genes or with drugs such as chloroquine, 
those cells undergo apoptosis more easily when they are treated with an additional 
death stimulus. I have now provided one potential mechanism in Chapter III to explain 
these effects in cancer cells where autophagy is blocked.  
Autophagy may determine the apoptotic threshold 
For almost 20 years, one of the recognized hallmarks of cancer has been 
evasion of apoptosis (Hanahan and Weinberg, 2000). This has often led to the 
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misconception that cancer cells must be generally resistant to apoptosis compared with 
their normal counterparts. However, the opposite is actually true, cancer cells are 
generally more sensitive to apoptosis than normal cells in part because oncogenes that 
drive tumor cell growth also tend to ‘prime’ them to cell death (Green and Evan, 2002).  
As we’ve discussed, cancer cells integrate environmental pro- and anti-apoptotic 
signals by using protein-protein interactions between BH3-only pro-apoptotic proteins, 
the apoptosis effectors BAX and BAK, and BCL-2 anti-apoptotic proteins. It is possible 
to directly measure the propensity of a given anti-cancer drug to release cytochrome c 
from mitochondria in cancer cells using a technique called BH3 profiling, which can 
predict therapeutic responses in patients (Ni Chonghaile et al., 2011). Cytotoxic drugs 
act by pushing cancer cells to commit apoptosis, and are beneficial in many cancer 
types and continue to be widely used (Letai, 2015). Additionally, targeted therapies 
capitalize on specific cancer cell vulnerabilities to promote cancer cell death. It is 
important to understand how both cytotoxic and targeted therapies affect apoptosis 
threshold to commit cancer cells to undergo apoptosis. 
Studies by the Letai laboratory have determined that cancer cells reside at 
varying distances away from falling off of a proverbial ‘cliff’ to undergoing apoptosis—for 
example, some cells are highly primed to undergo apoptosis and therefore close to the 
cliff’s edge. Which molecular mechanisms determine a cell’s distance from the cliff? 
What determines the apoptotic threshold of cancer cells in a population? Could it be that 
autophagy—an evolutionarily conserved process connected to apoptosis—is 
responsible for setting the apoptotic threshold? The findings in Chapter III and IV add to 
our understanding of what influences a cell’s decision to live or die. From this work 
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(Fitzwalter et al., 2018) showing that autophagy and apoptosis are directly linked via 
FOXO3a transcriptionally regulating PUMA levels, and previous works from the 
Thorburn laboratory (Gump et al., 2014), I pose the following hypothesis: the level of 
autophagy preceding a death stimulus directly determines how primed that cell is to 
undergo apoptosis. Consistent with this hypothesis, is my data showing that I can 
‘unlink’ autophagy and apoptosis by mutating the FHRE in the PUMA gene to reverse 
the apoptosis sensitivity conferred by autophagy inhibition (Fitzwalter et al., 2018).  
Studies moving forward should utilize a method described above, BH3 profiling, 
to determine how primed cells are to undergo apoptosis and if the amount of autophagy 
flux is directly related. All cells undergo a basal amount of autophagy flux at any given 
moment; suppose that we could sort these cells into high and low autophagy and then 
subject them to BH3 profiling. If autophagy determines the apoptotic threshold, then I 
would expect that cells with low flux may be more primed to undergo apoptosis than 
high autophagy cells. Answering these questions may provide an explanation for why 
inhibiting autophagy in cancer patients is proving to be beneficial.  
ASAP can rapidly block autophagy 
Existing methods to inhibit autophagy are either slow (~48 hours), non-specific, 
or both; the experiments performed in Chapters III-IV used shRNA knockdown, 
CRISPR/Cas9-mediated knockout, or pharmacological blockage of autophagy. Although 
using these methods allowed me to uncover interesting biology linking autophagy and 
apoptosis, as I will discuss, some questions remain unanswerable using these existing 
methods. There is a need to develop genetic tools to rapidly or spatially manipulate 
autophagy, either inter- or intracellularly. With the advent of a new tool, future studies 
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could test hypotheses that are not possible to investigate with current methods of 
autophagy inhibition.  
To begin to tackle unanswered questions in the field of autophagy and cell death, 
I describe in Chapter VI a novel optogenetic system that can rapidly inhibit autophagy 
with light in cancer cells using 405 nm light. By utilizing a SNARE protein with an N-
terminal truncation (STX17∆NTD) that has been described previously (Uematsu et al., 
2017), the fusion of the autophagosome and the lysosome is blocked. In the dark, 
STX17∆NTD is sequestered at the mitochondrion away from sites of autophagosome-
lysosome fusion, and autophagy is functional. However, upon 405nm light incidence, 
STX17∆NTD is released and can act to inhibit autophagosome-lysosome fusion. An 
essential feature of this system is the use of an optogenetic tool called PhoCL (Zhang et 
al., 2017). I combined the two tools, PhoCL and STX17∆NTD, and termed this 
optogenetic system ASAP for Autophagic SNARE for Abrupt Photoinhibition (Figure 
6.1). Next, we used biochemistry to show that I could use ASAP to achieve autophagy 
inhibition in multiple different cancer cell lines, resulting in an increase in the autophagy 
substrates SQSTM1/p62, FOXO3a, and an increase in LC3-II levels (Figure 6.2). To 
provide functional evidence that ASAP is inhibiting autophagy, I used the BT549 cancer 
cell that is dependent on autophagy for its survival to test ASAP (Figure 6.3). We 
hypothesized that if I expressed ASAP in BT549 cells and expose them to 405nm light 
(compared to a dark control), they would undergo cell death. Indeed, I show that ASAP 
can dose-dependently cause rapid and transient autophagy inhibition to kill autophagy-
dependent cancer cells (Figure 6.4).  
Previous studies (Fitzwalter et al., 2018) showed that autophagy inhibition could 
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change the mode of action of the anti-cancer drug Nutlin from growth arrest to 
apoptosis. I wondered if I could achieve this same effect on cells using the ASAP 
optogenetic system to inhibit autophagy, and found that in ASAP cells the combination 
of 405 nm light and Nutlin treatment resulted in more growth arrest and apoptosis 
compared to that of the ASAP control cells (Figure 6.5). These results demonstrate that 
ASAP cells treated with light can effectively inhibit autophagy to improve the anti-cancer 
drug Nutlin.  
I hypothesized that ASAP is working very rapidly (on the time scale of minutes) 
upon photostimulation to inhibit the autophagosome-lysosome fusion. Currently, there 
are no methods to measure autophagy in real time and thus test how quickly or slowly 
an inhibitor works. I developed another tool to determine when autophagy is inhibited by 
monitoring the delivery of new substrates to the lysosome for degradation in real-time 
by confocal microscopy. I used a fluorophore called pHRed that is strongly excited by a 
561nm laser only when it resides in a low pH environment, such as a lysosome. 
However, at a pH-neutral environment, pHRed shows little to no fluorescence. I tagged 
the autophagy receptor and cargo protein p62/SQSTM1 with pHRed and observed 
strong co-localization of pHRed-p62 with lysosomes (Figure 6.6). I hypothesized that I 
could monitor the nascent delivery of p62 to lysosomes if I utilized a photobleaching 
workflow to observe Fluorescence Recover After Photobleaching (FRAP) (Figure 6.6). 
Photobleaching is an irreversible destruction of fluorescence in a region caused by short 
exposures to a high-intensity laser. I observed pHRed-p62 localized to lysosomes and 
upon photobleaching a select region of the cell, I observed rapid recovery of 
fluorescence. These results suggest that any fluorescence recovery is a result of new 
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pHRed-p62 molecules being delivered to lysosomes, and thus provides a tool for us to 
study autophagy substrate delivery in real time.  
Using FRAP gives us the ability to monitor autophagy substrate delivery to 
lysosomes. This includes the ability to monitor any autophagy cargo in real time, for 
example the delivery of mitochondria (pHRed-Fis1) or NCOA4 (pHRed-NCOA4) to 
lysosomes. This powerful tool allowed us to determine that lysosomes can 
accommodate multiple autophagosome fusion events (Figure 6.7), and to test the 
hypothesis that ASAP is acting rapidly to block pHRed-p62 delivery to lysosomes via 
autophagic delivery (Figure 6.8). The ASAP optogenetic system and FRAP workflow of 
pHRed-p62 separately or in combination have capabilities to address unresolved 
questions in the field of autophagy and cell death. Below, I will give an overview of the 
potential of future uses of the ASAP system. 
It is known that cancer cells induce autophagy quickly in response to 
chemotherapy drugs and radiation, but the effect of this chemotherapy-induced 
autophagy on cell death is not known (Bristol et al., 2012; Gewirtz, 2014; Wilson et al., 
2011). Some studies suggest that induced autophagy during apoptosis may be 
protective (Lindqvist et al., 2018; Lindqvist et al., 2014). Is this drug-induced autophagy 
promoting cell death, preventing it, or simply an inconsequential side effect? Is the drug-
induced autophagy molecularly distinct from other forms of autophagy, like starvation-
inducted autophagy? 
A rapid genetic system is necessary to address these questions, and is not 
possible with current methods. Using ASAP, I can determine the effect of specifically 
blocking drug-induced autophagy on apoptosis; blocking drug-induced autophagy with 
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light may result in augmented, decreased, or unaffected apoptosis compared to cells 
kept in the dark. If inhibiting drug-induced autophagy using ASAP results in more 
apoptosis, this would suggest that the autophagy is protecting the cell from the 
impending death. However, if less apoptosis occurs, this suggests that autophagy may 
be important for mediating the cell death. Either of these scenarios may uncover the 
unknown significance drug-induced autophagy, and could have an influence on the way 
patients are treated with autophagy inhibitors in the clinic.   
Future studies using ASAP could also uncover the immediate transcriptional 
changes, post-translational modifications, and cellular adaptation mechanisms following 
genetic autophagy inhibition. Additionally, ASAP could be used in vivo in transparent 
organisms, like zebrafish to test the contribution of autophagy to physiological 
processes. One possibility would be to express ASAP under a cell type-specific 
promoter to determine the role of autophagy in a particular tissue or during a particular 
time during development. Zebrafish models of neurodegeneration, cancer, and ageing 
are currently available to use for these studies (Martin-Jimenez et al., 2015; Mione and 
Trede, 2010). 
Concluding remarks  
In conclusion, I have described a fundamental molecular mechanism that links 
autophagy and apoptosis, and I leverage this mechanism to show that autophagy 
inhibition causes anti-cancer drugs to become more effective at inducing apoptosis. In 
addition to increased apoptosis sensitization, this mechanism is able to change the 
mode of action of an MDM2-targeted drug from growth arrest to cell death, suggesting 
that combining Nutlin therapies and autophagy inhibition could be especially efficacious. 
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All of these effects are reliant on a single FOXO3a binding site in the PUMA gene; 
simply mutating this site is sufficient to reverse these biological effects. Equally 
surprising is the finding that a transcription factor, FOXO3a, known to regulate many 
gene targets would mediate the connection between autophagy and apoptosis through 
transactivation of a single BH3 protein, PUMA. Further, the regulation of FOXO3a 
activity by autophagic degradation, but not proteasomal degradation, suggest that there 
are still interesting aspects of FOXO3a biology to be uncovered. To my knowledge, this 
work provides the first demonstration that autophagy can selectively degrade a 
transcription factor to influence its transcriptional activity. 
I have discussed work from the Letai laboratory and stressed the importance of 
the apoptosis threshold in cancer cells, and how chemotherapies are effective by taking 
advantage of the difference in normal cells and cancer cells. The most important 
implication of this Thesis work is that autophagy directly determines the apoptotic 
threshold in cancer cells, and by manipulating autophagy we can push cells to commit 
to apoptosis. By combining autophagy inhibitors and anti-cancer drugs, we create an 
opportunity to improve cancer therapeutics by expanding the therapeutic window.  
In this Thesis, I show the development of a powerful optogenetic system, ASAP, 
to rapidly inhibit autophagosome-lysosome fusion. Current methods to block autophagy 
are slow and non-specific, but ASAP provides both rapid and genetic autophagy 
inhibition with small light doses. The advent of this method will allow us to gain 
mechanistic insight into how autophagy regulates cell death and other cellular 
processes.  
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This thesis provides a body of work that begins to make sense of the molecular 
links between autophagy and cells death. Continued efforts to gain mechanistic insight 
will bring us closer to understanding the precise consequences of altering autophagy in 
patients; we have only just begun to explore the potential of targeting this evolutionarily-






























Amente, S., Zhang, J., Lavadera, M.L., Lania, L., Avvedimento, E.V., and Majello, B. 
(2011). Myc and PI3K/AKT signaling cooperatively repress FOXO3a-dependent PUMA 
and GADD45a gene expression. Nucleic Acids Res 39, 9498-9507. 
Aoki, M., Jiang, H., and Vogt, P.K. (2004). Proteasomal degradation of the FoxO1 
transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc Natl 
Acad Sci U S A 101, 13613-13617. 
Arasaki, K., Shimizu, H., Mogari, H., Nishida, N., Hirota, N., Furuno, A., Kudo, Y., Baba, 
M., Baba, N., Cheng, J., et al. (2015). A role for the ancient SNARE syntaxin 17 in 
regulating mitochondrial division. Dev Cell 32, 304-317. 
Bago, R., Malik, N., Munson, M.J., Prescott, A.R., Davies, P., Sommer, E., Shpiro, N., 
Ward, R., Cross, D., Ganley, I.G., et al. (2014). Characterization of VPS34-IN1, a 
selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding 
SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase. The 
Biochemical journal 463, 413-427. 
Basit, F., Cristofanon, S., and Fulda, S. (2013). Obatoclax (GX15-070) triggers 
necroptosis by promoting the assembly of the necrosome on autophagosomal 
membranes. Cell Death Differ 20, 1161-1173. 
Berry, D.L., and Baehrecke, E.H. (2007). Growth arrest and autophagy are required for 
salivary gland cell degradation in Drosophila. Cell 131, 1137-1148. 
Bray, K., Mathew, R., Lau, A., Kamphorst, J.J., Fan, J., Chen, J., Chen, H.-Y., Ghavami, 
A., Stein, M., Dipaola, R.S., et al. (2012). Autophagy suppresses RIP kinase-dependent 
necrosis enabling survival to mTOR inhibition. PloS one 7, e41831. 
Bristol, M.L., Di, X., Beckman, M.J., Wilson, E.N., Henderson, S.C., Maiti, A., Fan, Z., 
and Gewirtz, D.A. (2012). Dual functions of autophagy in the response of breast tumor 
cells to radiation: cytoprotective autophagy with radiation alone and cytotoxic autophagy 
in radiosensitization by vitamin D 3. Autophagy 8, 739-753. 
Brunet, A., Bonni, A., Zigmond, M.J., Lin, M.Z., Juo, P., Hu, L.S., Anderson, M.J., 
Arden, K.C., Blenis, J., and Greenberg, M.E. (1999). Akt promotes cell survival by 
phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857-868. 
 125 
Brunet, A., Park, J., Tran, H., Hu, L.S., Hemmings, B.A., and Greenberg, M.E. (2001). 
Protein kinase SGK mediates survival signals by phosphorylating the forkhead 
transcription factor FKHRL1 (FOXO3a). Mol Cell Biol 21, 952-965. 
Burgess, A., Chia, K.M., Haupt, S., Thomas, D., Haupt, Y., and Lim, E. (2016). Clinical 
Overview of MDM2/X-Targeted Therapies. Front Oncol 6, 7. 
Calnan, D.R., and Brunet, A. (2008). The FoxO code. Oncogene 27, 2276-2288. 
Chen, D., Tong, J., Yang, L., Wei, L., Stolz, D.B., Yu, J., Zhang, J., and Zhang, L. 
(2018). PUMA amplifies necroptosis signaling by activating cytosolic DNA sensors. Proc 
Natl Acad Sci U S A 115, 3930-3935. 
Clark, K.L., Halay, E.D., Lai, E., and Burley, S.K. (1993). Co-crystal structure of the 
HNF-3/fork head DNA-recognition motif resembles histone H5. Nature 364, 412-420. 
Collins, K.P., Jackson, K.M., and Gustafson, D.L. (2018). Hydroxychloroquine: A 
Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related 
Autophagy Modulation. J Pharmacol Exp Ther 365, 447-459. 
Denton, D., Shravage, B., Simin, R., Mills, K., Berry, D.L., Baehrecke, E.H., and Kumar, 
S. (2009). Autophagy, not apoptosis, is essential for midgut cell death in Drosophila. 
Curr Biol 19, 1741-1746. 
Donlon, T.A., Curb, J.D., He, Q., Grove, J.S., Masaki, K.H., Rodriguez, B., Elliott, A., 
Willcox, D.C., and Willcox, B.J. (2012). FOXO3 gene variants and human aging: coding 
variants may not be key players. J Gerontol A Biol Sci Med Sci 67, 1132-1139. 
Dou, Z., Xu, C., Donahue, G., Shimi, T., Pan, J.-A., Zhu, J., Ivanov, A., Capell, B.C., 
Drake, A.M., Shah, P.P., et al. (2015). Autophagy mediates degradation of nuclear 
lamina. Nature 527, 105-109. 
Dowdle, W.E., Nyfeler, B., Nagel, J., Elling, R.A., Liu, S., Triantafellow, E., Menon, S., 
Wang, Z., Honda, A., Pardee, G., et al. (2014). Selective VPS34 inhibitor blocks 
autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis 
in vivo. Nature cell biology. 
Egan, D.F., Chun, M.G.H., Vamos, M., Zou, H., Rong, J., Miller, C.J., Lou, H.J., 
Raveendra-Panickar, D., Yang, C.-C., Sheffler, D.J., et al. (2015). Small Molecule 
 126 
Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates. 
Molecular Cell 59, 285-297. 
Eijkelenboom, A., Mokry, M., de Wit, E., Smits, L.M., Polderman, P.E., van Triest, M.H., 
van Boxtel, R., Schulze, A., de Laat, W., Cuppen, E., et al. (2013). Genome-wide 
analysis of FOXO3 mediated transcription regulation through RNA polymerase II 
profiling. Mol Syst Biol 9, 638. 
Elgendy, M., Sheridan, C., Brumatti, G., and Martin, S.J. (2011). Oncogenic ras-induced 
expression of noxa and beclin-1 promotes autophagic cell death and limits clonogenic 
survival. Molecular Cell 42, 23-35. 
Feng, Y., Yao, Z., and Klionsky, D.J. (2015). How to control self-digestion: 
transcriptional, post-transcriptional, and post-translational regulation of autophagy. 
Trends in cell biology 25, 354-363. 
Fitzwalter, B., E., and Thorburn, A. (2015a). Recent insights into cell death and 
autophagy. The FEBS journal 282, 4279-4288. 
Fitzwalter, B.E., and Thorburn, A. (2015b). Recent insights into cell death and 
autophagy. FEBS J 282, 4279-4288. 
Fitzwalter, B.E., and Thorburn, A. (2018). FOXO3 links autophagy to apoptosis. 
Autophagy 14, 1467-1468. 
Fitzwalter, B.E., Towers, C.G., Sullivan, K.D., Andrysik, Z., Hoh, M., Ludwig, M., O'Prey, 
J., Ryan, K.M., Espinosa, J.M., Morgan, M.J., et al. (2018). Autophagy Inhibition 
Mediates Apoptosis Sensitization in Cancer Therapy by Relieving FOXO3a Turnover. 
Dev Cell 44, 555-565 e553. 
Fricker, M., O'Prey, J., Tolkovsky, A.M., and Ryan, K.M. (2010). Phosphorylation of 
Puma modulates its apoptotic function by regulating protein stability. Cell Death Dis 1, 
e59. 
Fuchs, Y., and Steller, H. (2015). Live to die another way: modes of programmed cell 
death and the signals emanating from dying cells. Nat Rev Mol Cell Biol 16, 329-344. 
Füllgrabe, J., Klionsky, D.J., and Joseph, B. (2014). The return of the nucleus: 
transcriptional and epigenetic control of autophagy. Nat Rev Mol Cell Biol 15, 65-74. 
 127 
Furuyama, T., Nakazawa, T., Nakano, I., and Mori, N. (2000). Identification of the 
differential distribution patterns of mRNAs and consensus binding sequences for mouse 
DAF-16 homologues. Biochem J 349, 629-634. 
Galluzzi, L., Pietrocola, F., Bravo-San Pedro, J.M., Amaravadi, R.K., Baehrecke, E.H., 
Cecconi, F., Codogno, P., Debnath, J., Gewirtz, D.A., Karantza, V., et al. (2015). 
Autophagy in malignant transformation and cancer progression. The EMBO journal. 
Garnett, M.J., Edelman, E.J., Heidorn, S.J., Greenman, C.D., Dastur, A., Lau, K.W., 
Greninger, P., Thompson, I.R., Luo, X., Soares, J., et al. (2012). Systematic 
identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-
575. 
Gewirtz, D.A. (2014). The four faces of autophagy: implications for cancer therapy. 
Cancer Res 74, 647-651. 
Giampazolias, E., Zunino, B., Dhayade, S., Bock, F., Cloix, C., Cao, K., Roca, A., 
Lopez, J., Ichim, G., Proics, E., et al. (2017). Mitochondrial permeabilization engages 
NF-kappaB-dependent anti-tumour activity under caspase deficiency. Nat Cell Biol 19, 
1116-1129. 
Goodall, M.L., Fitzwalter, B.E., Zahedi, S., Wu, M., Rodriguez, D., Mulcahy-Levy, J.M., 
Green, D.R., Morgan, M., Cramer, S.D., and Thorburn, A. (2016). The Autophagy 
Machinery Controls Cell Death Switching between Apoptosis and Necroptosis. Dev Cell 
37, 337-349. 
Green, D.R., and Evan, G.I. (2002). A matter of life and death. Cancer Cell 1, 19-30. 
Green, D.R., Ferguson, T., Zitvogel, L., and Kroemer, G. (2009). Immunogenic and 
tolerogenic cell death. Nat Rev Immunol 9, 353-363. 
Gu, W., Wan, D., Qian, Q., Yi, B., He, Z., Gu, Y., Wang, L., and He, S. (2014). Ambra1 
is an essential regulator of autophagy and apoptosis in SW620 cells: pro-survival role of 
Ambra1. PLoS One 9, e90151. 
Gump, J.M., Staskiewicz, L., Morgan, M.J., Bamberg, A., Riches, D.W.H., and 
Thorburn, A. (2014). Autophagy variation within a cell population determines cell fate 
through selective degradation of Fap-1. Nat Cell Biol 16, 47-54. 
 128 
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70. 
Hara, T., Nakamura, K., Matsui, M., Yamamoto, A., Nakahara, Y., Suzuki-Migishima, R., 
Yokoyama, M., Mishima, K., Saito, I., Okano, H., et al. (2006). Suppression of basal 
autophagy in neural cells causes neurodegenerative disease in mice. Nature 441, 885-
889. 
Henderson, S.T., and Johnson, T.E. (2001). daf-16 integrates developmental and 
environmental inputs to mediate aging in the nematode Caenorhabditis elegans. Curr 
Biol 11, 1975-1980. 
Hershko, T., and Ginsberg, D. (2004). Up-regulation of Bcl-2 homology 3 (BH3)-only 
proteins by E2F1 mediates apoptosis. J Biol Chem 279, 8627-8634. 
Huang, B., Deo, D., Xia, M., and Vassilev, L.T. (2009). Pharmacologic p53 activation 
blocks cell cycle progression but fails to induce senescence in epithelial cancer cells. 
Mol Cancer Res 7, 1497-1509. 
Huang, H., Regan, K.M., Wang, F., Wang, D., Smith, D.I., van Deursen, J.M., and 
Tindall, D.J. (2005). Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-
mediated degradation. Proc Natl Acad Sci U S A 102, 1649-1654. 
Huang, H., and Tindall, D.J. (2007). Dynamic FoxO transcription factors. J Cell Sci 120, 
2479-2487. 
Huang, H., and Tindall, D.J. (2011). Regulation of FOXO protein stability via 
ubiquitination and proteasome degradation. Biochim Biophys Acta 1813, 1961-1964. 
Ichim, G., Lopez, J., Ahmed, S.U., Muthalagu, N., Giampazolias, E., Delgado, M.E., 
Haller, M., Riley, J.S., Mason, S.M., Athineos, D., et al. (2015). Limited mitochondrial 
permeabilization causes DNA damage and genomic instability in the absence of cell 
death. Mol Cell 57, 860-872. 
Itakura, E., Kishi-Itakura, C., and Mizushima, N. (2012). The Hairpin-type Tail-Anchored 
SNARE Syntaxin 17 Targets to Autophagosomes for Fusion with 
Endosomes/Lysosomes. Cell 151, 1256-1269. 
 129 
Kimura, S., Noda, T., and Yoshimori, T. (2007). Dissection of the autophagosome 
maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. 
Autophagy 3, 452-460. 
Komarnitsky, P., Cho, E.J., and Buratowski, S. (2000). Different phosphorylated forms 
of RNA polymerase II and associated mRNA processing factors during transcription. 
Genes Dev 14, 2452-2460. 
Komatsu, M., Waguri, S., Chiba, T., Murata, S., Iwata, J., Tanida, I., Ueno, T., Koike, 
M., Uchiyama, Y., Kominami, E., et al. (2006). Loss of autophagy in the central nervous 
system causes neurodegeneration in mice. Nature 441, 880-884. 
Letai, A. (2015). Cell Death and Cancer Therapy: Don't Forget to Kill the Cancer Cell! 
Clin Cancer Res 21, 5015-5020. 
Levy, J.M.M., Towers, C.G., and Thorburn, A. (2017a). Targeting autophagy in cancer. 
Nature Reviews Cancer 17, 528-542. 
Levy, J.M.M., Towers, C.G., and Thorburn, A. (2017b). Targeting autophagy in cancer. 
Nat Rev Cancer 17, 528-542. 
Li, J., Tewari, M., Vidal, M., and Lee, S.S. (2007). The 14-3-3 protein FTT-2 regulates 
DAF-16 in Caenorhabditis elegans. Dev Biol 301, 82-91. 
Li, Z., Zhao, J., Tikhanovich, I., Kuravi, S., Helzberg, J., Dorko, K., Roberts, B., Kumer, 
S., and Weinman, S.A. (2016). Serine 574 phosphorylation alters transcriptional 
programming of FOXO3 by selectively enhancing apoptotic gene expression. Cell Death 
Differ 23, 583-595. 
Liang, X., Potter, J., Kumar, S., Zou, Y., Quintanilla, R., Sridharan, M., Carte, J., Chen, 
W., Roark, N., Ranganathan, S., et al. (2015). Rapid and highly efficient mammalian cell 
engineering via Cas9 protein transfection. J Biotechnol 208, 44-53. 
Lin, K., Dorman, J.B., Rodan, A., and Kenyon, C. (1997). daf-16: An HNF-3/forkhead 
family member that can function to double the life-span of Caenorhabditis elegans. 
Science 278, 1319-1322. 
 130 
Lindqvist, L.M., Frank, D., McArthur, K., Dite, T.A., Lazarou, M., Oakhill, J.S., Kile, B.T., 
and Vaux, D.L. (2018). Autophagy induced during apoptosis degrades mitochondria and 
inhibits type I interferon secretion. Cell Death Differ 25, 782-794. 
Lindqvist, L.M., Heinlein, M., Huang, D.C., and Vaux, D.L. (2014). Prosurvival Bcl-2 
family members affect autophagy only indirectly, by inhibiting Bax and Bak. Proc Natl 
Acad Sci U S A 111, 8512-8517. 
Liu, X., He, Y., Li, F., Huang, Q., Kato, T.A., Hall, R.P., and Li, C.-Y. (2015). Caspase-3 
promotes genetic instability and carcinogenesis. Molecular Cell 58, 284-296. 
Liu, Y., Shoji-Kawata, S., Sumpter, R.M., Jr., Wei, Y., Ginet, V., Zhang, L., Posner, B., 
Tran, K.A., Green, D.R., Xavier, R.J., et al. (2013). Autosis is a Na+,K+-ATPase-
regulated form of cell death triggered by autophagy-inducing peptides, starvation, and 
hypoxia-ischemia. Proc Natl Acad Sci U S A 110, 20364-20371. 
Maiese, K. (2015). FoxO proteins in the nervous system. Anal Cell Pathol (Amst) 2015, 
569392. 
Martin-Jimenez, R., Campanella, M., and Russell, C. (2015). New zebrafish models of 
neurodegeneration. Curr Neurol Neurosci Rep 15, 33. 
Matsuzaki, H., Daitoku, H., Hatta, M., Tanaka, K., and Fukamizu, A. (2003). Insulin-
induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc 
Natl Acad Sci U S A 100, 11285-11290. 
Mauthe, M., Orhon, I., Rocchi, C., Zhou, X., Luhr, M., Hijlkema, K.J., Coppes, R.P., 
Engedal, N., Mari, M., and Reggiori, F. (2018). Chloroquine inhibits autophagic flux by 
decreasing autophagosome-lysosome fusion. Autophagy 14, 1435-1455. 
Maycotte, P., Gearheart, C.M., Barnard, R., Aryal, S., Mulcahy Levy, J.M., Fosmire, 
S.P., Hansen, R.J., Morgan, M.J., Porter, C.C., Gustafson, D.L., et al. (2014). STAT3-
mediated autophagy dependence identifies subtypes of breast cancer where autophagy 
inhibition can be efficacious. Cancer Res 74, 2579-2590. 
Melino, G., Bernassola, F., Ranalli, M., Yee, K., Zong, W.X., Corazzari, M., Knight, R.A., 
Green, D.R., Thompson, C., and Vousden, K.H. (2004). p73 Induces apoptosis via 
PUMA transactivation and Bax mitochondrial translocation. J Biol Chem 279, 8076-
8083. 
 131 
Mione, M.C., and Trede, N.S. (2010). The zebrafish as a model for cancer. Dis Model 
Mech 3, 517-523. 
Mizushima, N. (2007). Autophagy: process and function. Genes Dev 21, 2861-2873. 
Mizushima, N., Noda, T., Yoshimori, T., Tanaka, Y., Ishii, T., George, M.D., Klionsky, 
D.J., Ohsumi, M., and Ohsumi, Y. (1998). A protein conjugation system essential for 
autophagy. Nature 395, 395-398. 
Nakano, K., and Vousden, K.H. (2001). PUMA, a novel proapoptotic gene, is induced by 
p53. Mol Cell 7, 683-694. 
Nelson, C., and Baehrecke, E.H. (2014). Eaten to death. The FEBS journal 281, 5411-
5417. 
Nezis, I.P., Shravage, B.V., Sagona, A.P., Lamark, T., Bjørkøy, G., Johansen, T., 
Rusten, T.E., Brech, A., Baehrecke, E.H., and Stenmark, H. (2010). Autophagic 
degradation of dBruce controls DNA fragmentation in nurse cells during late Drosophila 
melanogaster oogenesis. J Cell Biol 190, 523-531. 
Ni Chonghaile, T., Sarosiek, K.A., Vo, T.T., Ryan, J.A., Tammareddi, A., Moore Vdel, 
G., Deng, J., Anderson, K.C., Richardson, P., Tai, Y.T., et al. (2011). Pretreatment 
mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. 
Science 334, 1129-1133. 
O'Prey, J., Sakamaki, J., Baudot, A.D., New, M., Van Acker, T., Tooze, S.A., Long, J.S., 
and Ryan, K.M. (2017). Application of CRISPR/Cas9 to Autophagy Research. Methods 
Enzymol 588, 79-108. 
Obsilova, V., Vecer, J., Herman, P., Pabianova, A., Sulc, M., Teisinger, J., Boura, E., 
and Obsil, T. (2005). 14-3-3 Protein interacts with nuclear localization sequence of 
forkhead transcription factor FoxO4. Biochemistry 44, 11608-11617. 
Ogg, S., Paradis, S., Gottlieb, S., Patterson, G.I., Lee, L., Tissenbaum, H.A., and 
Ruvkun, G. (1997). The Fork head transcription factor DAF-16 transduces insulin-like 
metabolic and longevity signals in C. elegans. Nature 389, 994-999. 
 132 
Oral, O., Oz-Arslan, D., Itah, Z., Naghavi, A., Deveci, R., Karacali, S., and Gozuacik, D. 
(2012). Cleavage of Atg3 protein by caspase-8 regulates autophagy during receptor-
activated cell death. Apoptosis 17, 810-820. 
Paris, R., Henry, R.E., Stephens, S.J., McBryde, M., and Espinosa, J.M. (2008). 
Multiple p53-independent gene silencing mechanisms define the cellular response to 
p53 activation. Cell Cycle 7, 2427-2433. 
Pattingre, S., Tassa, A., Qu, X., Garuti, R., Liang, X.H., Mizushima, N., Packer, M., 
Schneider, M.D., and Levine, B. (2005). Bcl-2 antiapoptotic proteins inhibit beclin 1-
dependent autophagy. Cell 122, 927-939. 
Plas, D.R., and Thompson, C.B. (2003). Akt activation promotes degradation of tuberin 
and FOXO3a via the proteasome. J Biol Chem 278, 12361-12366. 
Ronan, B., Flamand, O., Vescovi, L., Dureuil, C., Durand, L., Fassy, F., Bachelot, M.-F., 
Lamberton, A., Mathieu, M., Bertrand, T., et al. (2014). A highly potent and selective 
Vps34 inhibitor alters vesicle trafficking and autophagy. Nat Chem Biol 10, 1013-1019. 
Shin, H.J., Kim, H., Oh, S., Lee, J.G., Kee, M., Ko, H.J., Kweon, M.N., Won, K.J., and 
Baek, S.H. (2016). AMPK-SKP2-CARM1 signalling cascade in transcriptional regulation 
of autophagy. Nature 534, 553-557. 
Staskiewicz, L., Thorburn, J., Morgan, M.J., and Thorburn, A. (2013). Inhibiting 
autophagy by shRNA knockdown: Cautions and recommendations. Autophagy 9. 
Sullivan, K.D., Palaniappan, V.V., and Espinosa, J.M. (2015). ATM regulates cell fate 
choice upon p53 activation by modulating mitochondrial turnover and ROS levels. Cell 
Cycle 14, 56-63. 
Tait, S.W., Ichim, G., and Green, D.R. (2014). Die another way--non-apoptotic 
mechanisms of cell death. J Cell Sci 127, 2135-2144. 
Tait, S.W.G., Parsons, M.J., Llambi, F., Bouchier-Hayes, L., Connell, S., Muñoz-Pinedo, 
C., and Green, D.R. (2010). Resistance to caspase-independent cell death requires 
persistence of intact mitochondria. Dev Cell 18, 802-813. 
 133 
Takeshige, K., Baba, M., Tsuboi, S., Noda, T., and Ohsumi, Y. (1992). Autophagy in 
yeast demonstrated with proteinase-deficient mutants and conditions for its induction. J 
Cell Biol 119, 301-311. 
Tang, H.L., Tang, H.M., Fung, M.C., and Hardwick, J.M. (2015). In vivo CaspaseTracker 
biosensor system for detecting anastasis and non-apoptotic caspase activity. Scientific 
reports 5, 9015. 
Tang, Z., Takahashi, Y., Chen, C., Liu, Y., He, H., Tsotakos, N., Serfass, J.M., Gebru, 
M.T., Chen, H., Young, M.M., et al. (2017). Atg2A/B deficiency switches cytoprotective 
autophagy to non-canonical caspase-8 activation and apoptosis. Cell Death Differ 24, 
2127-2138. 
Tantama, M., Hung, Y.P., and Yellen, G. (2011). Imaging intracellular pH in live cells 
with a genetically encoded red fluorescent protein sensor. J Am Chem Soc 133, 10034-
10037. 
Thorburn, J., Andrysik, Z., Staskiewicz, L., Gump, J., Maycotte, P., Oberst, A., Green, 
D.R., Espinosa, J.M., and Thorburn, A. (2014). Autophagy controls the kinetics and 
extent of mitochondrial apoptosis by regulating PUMA levels. Cell Rep 7, 45-52. 
Tisato, V., Voltan, R., Gonelli, A., Secchiero, P., and Zauli, G. (2017). MDM2/X 
inhibitors under clinical evaluation: perspectives for the management of hematological 
malignancies and pediatric cancer. J Hematol Oncol 10, 133. 
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, 
B.T., Qing, W., Packman, K., et al. (2006). Small-molecule MDM2 antagonists reveal 
aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 
103, 1888-1893. 
Towers, C.G., and Thorburn, A. (2016). Therapeutic Targeting of Autophagy. 
EBioMedicine 14, 15-23. 
Tsukada, M., and Ohsumi, Y. (1993). Isolation and characterization of autophagy-
defective mutants of Saccharomyces cerevisiae. FEBS Lett 333, 169-174. 
Uematsu, M., Nishimura, T., Sakamaki, Y., Yamamoto, H., and Mizushima, N. (2017). 
Accumulation of undegraded autophagosomes by expression of dominant-negative 
STX17 (syntaxin 17) mutants. Autophagy 13, 1452-1464. 
 134 
van der Horst, A., Tertoolen, L.G., de Vries-Smits, L.M., Frye, R.A., Medema, R.H., and 
Burgering, B.M. (2004). FOXO4 is acetylated upon peroxide stress and deacetylated by 
the longevity protein hSir2(SIRT1). J Biol Chem 279, 28873-28879. 
Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., and Kroemer, G. (2010). Molecular 
mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 11, 
700-714. 
Warr, M.R., Binnewies, M., Flach, J., Reynaud, D., Garg, T., Malhotra, R., Debnath, J., 
and Passegue, E. (2013a). FOXO3A directs a protective autophagy program in 
haematopoietic stem cells. Nature 494, 323-327. 
Warr, M.R., Binnewies, M., Flach, J., Reynaud, D., Garg, T., Malhotra, R., Debnath, J., 
and Passegué, E. (2013b). FOXO3A directs a protective autophagy program in 
haematopoietic stem cells. Nature. 
Wei, Y., Pattingre, S., Sinha, S., Bassik, M., and Levine, B. (2008). JNK1-mediated 
phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell 30, 678-688. 
Weigel, D., Jurgens, G., Kuttner, F., Seifert, E., and Jackle, H. (1989). The homeotic 
gene fork head encodes a nuclear protein and is expressed in the terminal regions of 
the Drosophila embryo. Cell 57, 645-658. 
Willcox, B.J., Donlon, T.A., He, Q., Chen, R., Grove, J.S., Yano, K., Masaki, K.H., 
Willcox, D.C., Rodriguez, B., and Curb, J.D. (2008). FOXO3A genotype is strongly 
associated with human longevity. Proc Natl Acad Sci U S A 105, 13987-13992. 
Williams, S.A., and McConkey, D.J. (2003). The proteasome inhibitor bortezomib 
stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. 
Cancer Res 63, 7338-7344. 
Wilson, E.N., Bristol, M.L., Di, X., Maltese, W.A., Koterba, K., Beckman, M.J., and 
Gewirtz, D.A. (2011). A switch between cytoprotective and cytotoxic autophagy in the 
radiosensitization of breast tumor cells by chloroquine and vitamin D. Horm Cancer 2, 
272-285. 
Xuan, Z., and Zhang, M.Q. (2005). From worm to human: bioinformatics approaches to 
identify FOXO target genes. Mech Ageing Dev 126, 209-215. 
 135 
Yang, J.Y., Zong, C.S., Xia, W., Yamaguchi, H., Ding, Q., Xie, X., Lang, J.Y., Lai, C.C., 
Chang, C.J., Huang, W.C., et al. (2008). ERK promotes tumorigenesis by inhibiting 
FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10, 138-148. 
Yonekawa, T., Gamez, G., Kim, J., Tan, A.C., Thorburn, J., Gump, J., Thorburn, A., and 
Morgan, M.J. (2015). RIP1 negatively regulates basal autophagic flux through TFEB to 
control sensitivity to apoptosis. EMBO reports. 
You, H., Pellegrini, M., Tsuchihara, K., Yamamoto, K., Hacker, G., Erlacher, M., 
Villunger, A., and Mak, T.W. (2006). FOXO3a-dependent regulation of Puma in 
response to cytokine/growth factor withdrawal. J Exp Med 203, 1657-1663. 
Young, M.M., Takahashi, Y., Khan, O., Park, S., Hori, T., Yun, J., Sharma, A.K., Amin, 
S., Hu, C.-D., Zhang, J., et al. (2012). Autophagosomal membrane serves as platform 
for intracellular death-inducing signaling complex (iDISC)-mediated caspase-8 
activation and apoptosis. J Biol Chem 287, 12455-12468. 
Yu, J., and Zhang, L. (2008). PUMA, a potent killer with or without p53. Oncogene 27 
Suppl 1, S71-83. 
Yu, J., Zhang, L., Hwang, P.M., Kinzler, K.W., and Vogelstein, B. (2001). PUMA induces 
the rapid apoptosis of colorectal cancer cells. Mol Cell 7, 673-682. 
Yu, L., Alva, A., Su, H., Dutt, P., Freundt, E., Welsh, S., Baehrecke, E.H., and Lenardo, 
M.J. (2004). Regulation of an ATG7-beclin 1 Program of Autophagic Cell Death by 
Caspase-8. Science 304, 1500-1502. 
Yu, L., Wan, F., Dutta, S., Welsh, S., Liu, Z., Freundt, E., Baehrecke, E.H., and 
Lenardo, M. (2006). Autophagic programmed cell death by selective catalase 
degradation. Proc Natl Acad Sci U S A 103, 4952-4957. 
Yuan, Z., Becker, E.B., Merlo, P., Yamada, T., DiBacco, S., Konishi, Y., Schaefer, E.M., 
and Bonni, A. (2008). Activation of FOXO1 by Cdk1 in cycling cells and postmitotic 
neurons. Science 319, 1665-1668. 
Zhang, W., Lohman, A.W., Zhuravlova, Y., Lu, X., Wiens, M.D., Hoi, H., Yaganoglu, S., 
Mohr, M.A., Kitova, E.N., Klassen, J.S., et al. (2017). Optogenetic control with a 
photocleavable protein, PhoCl. Nat Methods 14, 391-394. 
 136 
Zhao, Y., Yang, J., Liao, W., Liu, X., Zhang, H., Wang, S., Wang, D., Feng, J., Yu, L., 
and Zhu, W.G. (2010). Cytosolic FoxO1 is essential for the induction of autophagy and 
tumour suppressor activity. Nat Cell Biol 12, 665-675. 
Zhu, Y., Zhao, L., Liu, L., Gao, P., Tian, W., Wang, X., Jin, H., Xu, H., and Chen, Q. 
(2010). Beclin 1 cleavage by caspase-3 inactivates autophagy and promotes apoptosis. 
Protein Cell 1, 468-477. 
 
